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The HER2+ breast cancer is an aggressive subtype of breast cancer arising 
from frequent amplification of HER2/neu gene that result in over-activation of 
HER pathways and cause uncontrolled cell proliferation and survival. The 
HER2+ breast cancer recurrence is largely due to resistance towards its 
therapy, which include the use of HER2-targeted agents such as Herceptin or 
Lapatinib. It is of importance to understand molecular mechanism towards 
therapeutic resistance in order to improve overall survival and relapse free 
survival in HER2+ breast cancer patients. Interestingly, a recent clinical data 
revealed positive association between HER2 status and tumour human Growth 
Hormone (hGH) in mammary carcinoma patients. It is thus worth to 
investigate on the potential role of autocrine expression of hGH and its 
therapeutic potential in HER2+ subtype breast cancer. 
Herein, this project determined the oncogenic capabilities of autocrine hGH in 
mediating malignant transformation and reducing sensitivity of HER2+ 
mammary carcinoma cells towards therapeutic agents such as Herceptin or 
Lapatinib in vitro. Functional in vitro assays including total cell number, cell 
viability, soft agar colony formation, growth in 3-dimension (3D) MatrigelTM 
and apoptosis demonstrated that forced expression of hGH significantly 
increases total cell number and enhances cell viability in 3D, and reduces 
apoptotic events in BT474 and SkBR3 HER2-amplified mammary carcinoma 
cells. Anchorage-independent growth is greatly enhanced in BT474 cells in the 
presence of autocrine hGH. One mechanism by which autocrine hGH exerts 
its oncogenic capacity in BT474 and SkBR3 HER2+ mammary carcinoma 
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cells is through stimulating tyrosine phosphorylation at Y1248 cytoplasmic 
residue, a major autophosphorylation site of HER2. Besides that, autocrine 
hGH expression provided selective growth advantage to BT474 and SkBR3 
cells from Herceptin- and Lapatinb-induced growth inhibition in vitro. 
Functional inhibition of endogenous hGH using GHR antagonists (B2036 and 
G120R) was attempted to examine the synergistic effect of blocking GH 
signalling and inhibiting HER2 activity together with HER2-targeted agents in 
HER2+ mammary carcinoma cells. Unfortunately, the cell line models used is 
either unresponsive to B2036 or selected out at early passage in the presence 
of G120R. Nevertheless, early passage stable cells transfected with G120R 
exhibited significant reduction in oncogenic capacity in proliferation and 
anchorage-independent growth, implying that blockage of circulating hGH is 
effective to decrease oncogenicity of HER2+ mammary carcinoma cells. 
Based on the experimental evidence, it suggests that hGH may play as 
additional prognostic marker and possess predictive role in HER2-
overexpressing breast cancer. Nevertheless, more work is required to verify 
the use of GHR antagonists in combination with HER2-targeted therapies in 
HER2+ tumours. Following that, preclinical and clinical studies can 
commence to assess feasibility and clinical relevance of introducing GH 
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Cancer development involves multiple processes where normal cell begin to 
grow uncontrollably and progressively giving rise to new or abnormal growth 
of cell mass referred to as tumour [1-3]. It is therefore characterized by a loss 
in normal cell control mechanisms that governs essential cellular functions 
such as survival, proliferation and differentiation, thereby resulting in 
disturbed cellular homeostasis [1, 2].  
According to GLOBOCAN 2008 database (version 1.2, 
http://globocan.iarc.fr), the leading cause of mortality worldwide is due to 
cancer, which accounts for 7.6 million deaths in addition to an approximated 
12.7 million new cancer cases were diagnosed. Each year, cancers of the lung, 
stomach, liver, colorectal and breast cause the most death among all other 
cancer types. It is projected that cancer mortality to rise to 21 million in 2030 
worldwide [4]. 
In Singapore, an estimate of 1 in 4 Singaporean dies of cancer. In addition, 14 
people die from cancer each day and 28 people are diagnosed with cancer 
every day (Singapore Cancer Registry, Interim Annual Registry Report, 
Trends in Cancer Incidence in Singapore, 2006-2010). Based on the Singapore 
Cancer Registry, the top 3 cancers diagnosed in Singapore for female are 
cancer of the Breast (29%), Colorectal (14%) and Lung (8%). For males, the 
top 3 cancers are Colorectal (18%), and Lung (16%) followed by Prostate 
2 
 
(11%) cancers (Singapore Cancer Registry, Interim Annual Registry Report, 
Trends in Cancer Incidence in Singapore, 2006-2010).  
In a normal healthy cell, the basic important cellular processes including cell 
division, motility, differentiation and proliferation are tightly controlled by 
cell-cell interaction, cell-extracellular matrix (ECM) and other 
microenvironmental cues (e.g. soluble hormones, cytokines, integrins and 
growth factors) [1-3, 5]. These interactions transduce many different signals 
that regulate important cellular functions for gene expression, differentiation, 
proliferation, motility and even cell death that are necessary to ensure tissue 
homeostasis [3]. However, in the case of cancer, it is evident that cells acquire 
biological capabilities or accumulate cellular mutations and/or defects that 
perturb the tightly controlled cellular regulatory mechanisms [1, 2].  
1.1.1 Hallmarks of Cancer 
In year 2000, Hanahan and Weinberg proposed six important hallmarks that 
are required and essential for the development and maintenance of cancer: (1) 
sustain proliferative signals, (2) evade growth suppressor through insensitivity 
to inhibitory growth signals, (3) resist cell death via apoptosis or programmed 
cell death, (4) limitless replication potential, (5) induce angiogenesis, and (6) 
activate tissue invasion and metastasis. During cancer development, cells 
begin to acquire some of these functional capabilities at some stage to 
successfully evade anti-cancer defence mechanisms and transform from 
normal human cells into a tumorigenic cell mass that can progress and become 
malignant cancer [1, 2] (Figure 1-1). Each essential cancer hallmark or 








Figure 1-1 Hallmarks of cancer (adopted with permission from Hanahan and Weinberg, 
2011) [2]. The hallmarks of cancer include: (1) Self-sufficient in growth signals, (2) 
Insensitivity to anti-growth signals, (3) Evading apoptosis, (4) Sustained angiogenesis, (5) 
Tissue invasion and metastasis and (6) Limitless replicative potential. 
1.1.1.1 Sustaining Proliferative Signal 
In normal physiological condition, cell undergoes active proliferation from 
quiescent state upon receiving appropriate stimuli or growth signals which 
include growth factors, components of the extracellular matrix, and cell-to-cell 
adhesion or interaction molecules [1]. Growth signals are transmitted and 
relied into the cell by binding to transmembrane receptors displayed on cell 
surface. Activated transmembrane receptors recruit intracellular adaptors and 
signalling molecules that rely signals downstream to activate proliferative 
pathway(s). The availability or release of growth signals are tightly controlled 
and regulated to ensure homeostasis of cell number for maintenance of normal 
tissue architecture [2]. However, in cancer, many oncogenes acquire the 
capability to mimic normal growth signalling that enables self-sufficient 
growth in sustained manner [2].  
Unlike normal cells in culture that depends and utilizes exogenous growth 
stimulation for maintenance of proper cellular and physiological behaviour, 
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cancer cells are less dependent on exogenous growth stimuli from their 
microenvironment for survival by generating their own growth signals [1, 2]. 
Cancer cells can synthesize growth factors creating a positive feedback 
signalling loop or autocrine stimulation that allows sustain survival [6]. 
Alternatively, cancer cells can secrete soluble factors or transmit signals to 
neighbouring stroma cells, which in turn supply growth factors back to the 
cancer cells in a paracrine mode [3, 6]. Sustainable proliferative signals are 
therefore available through these autocrine and/or paracrine stimulation from 
the cancer cells and/or neighbouring cells that eventually promote 
uncontrolled cell growth. 
Besides supplying themselves the growth signals, deregulation in the 
transmembrane growth receptors can contribute to sustainable proliferative 
signals in cancer cells. Deregulation in expression of tyrosine kinase growth 
receptors can result in over-expression of the receptors, thereby allowing 
cancer cells to become hyper-responsive to growth signal at low levels [1]. 
Moreover, cancer cells can utilize ligand-independent signalling through 
structural alteration of its receptors. Structural alteration such as mutation or 
truncation may render receptor constitutively active without the need for 
extracellular stimuli [7, 8]. Hence, growth signals will constantly be available 
and relied into the cells. Furthermore, mutation or up-regulation of 
downstream growth effectors such as transcription factors or other intracellular 
signalling molecules can result in constitutive activation of growth signal 
pathway(s). Acquisition of such capabilities allows cancer cells to circumvent 
the needs to stimulate growth pathway(s) via receptor-mediated signalling. 
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1.1.1.2 Evading Growth Suppressors  
Cell and tissue homeostasis are also governed by multiple anti-proliferative 
signals and negative feedback mechanisms that prevent cells from 
uncontrolled growth. Many of these anti-proliferation signals can be found to 
function in the cell cycle. 
Cell cycle is a series of an orderly process that allow cells to go through 
division and replication. It consists of G1 phase, S phase (synthesis), G2 phase 
and M phase (mitosis). As cells proceed through the cell cycle sequentially 
from G1 Æ S Æ G2 Æ M phases, checkpoint control mechanisms at the G1, 
G2 and M phases allow necessary cellular repair before ‘defected’ cell is 
allowed to transit to the next phase of its growth cycle. Defects in repair 
mechanisms at these cell cycle checkpoints or deregulation of molecules 
involved in cell cycle progression will lead to serious consequences. For 
instance, tumour suppressors are one mediator that negatively regulates 
proliferation and play important role in cell cycle checkpoints [9, 10]. The 
retinoblastoma-associated (Rb) protein is one of the tumour suppressors 
extensively studied, which function to inhibit cell cycle progression by 
repressing E2F transcription factors and prevent excessive cell growth [9]. The 
loss of such tumour suppressor gene function is thus disastrous or detrimental 
as cells with accumulated cancer-related mutation will be allowed to advance 
through the cell cycle aberrantly, ultimately leading to cancer [10]. Mutation 
in another tumour suppressor gene, p53 is also often observed to be associated 
to cancer [10]. The ability to evade growth suppressors can thus drive 
uncontrolled growth that is observed in cancer cells.  
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1.1.1.3 Resistance to Apoptosis 
Resistance towards apoptosis or programmed cell death (PCD) is another 
typical trait observed in almost all types of cancers. Apoptosis is a process 
where cells undergo death in response to physiological stress such as reactive 
oxygen species (ROS), DNA damage or injury [5]. Extracellular and 
intracellular environmental cues will activate anti-apoptotic or pro-apoptotic 
molecules that determine if a cell should survive or proceed to death pathway.  
Adequate apoptotic events are essentially important to maintain cell number 
and homeostasis. Excessive apoptosis can lead to atrophy while insufficient 
apoptotic event causes uncontrolled cell proliferation. Defective apoptosis has 
been shown to be implicated in diseases such as cancer. For instance, mutation 
or loss of pro-apoptotic regulators like the B-cell lymphoma 2 (BCL-2) have 
been demonstrated to allow cancer cell to evade apoptosis [11].  
Cancer cells not only acquired the ability to evade apoptosis, but also escape 
anoikis [5, 12, 13]. Anoikis is a normal cell death mechanism or program 
triggered by cell detachment from surrounding stroma or ECM [5, 12]. This 
mechanism prevents detached or dying cells from growing and colonizing at 
secondary site, thereby inhibiting aberrant cell growth or attachment to an 
inappropriate matrix subsequently [5, 12]. Resistance to anoikis allows 
anchorage-independent growth and survival during tumour dissemination. The 
ability to acquire anchorage-independent growth is prominently implicated in 
malignant transformation observed in many cancer-related studies [14, 15]. 
Deregulation of anoikis can be achieved via multiple mechanisms, which may 
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1.1.1.4 Limitless Replicative Potential 
A normal cell has limited lifespan or number of doublings before it enters 
senescence. As each cell cycle progresses, telomeres located at the end of each 
chromosome will be shortened until it reach a critical shortened length where 
DNA damage will be induced to signal cells to enter senescence [16]. Unlike 
normal cells, telomeres in cancer cells are maintained, which is achieved 
through upregulation of telomerase enzyme [17]. Therefore, cancers have the 
ability to divide continuously beyond their replicative potential, and may 
eventually lead to immortalization.  
Recent evidences in cancer studies have suggested presence of a small 
subpopulation of cells, referred to as cancer stem cells (CSC), within a tumour 
mass [18]. Like other progenitor stem cells, CSCs possess traits such as 
quiescent, maintain at G0 phase at cell cycle, self-renewal and able to undergo 
repeated proliferation through cell cycles. Acquisition of stem cell-like 
properties allow cancer cells to continuously drive tumour progression when it 
receive appropriate signals to exit G0, enter the cell cycle to begin replication, 
synthesize new cancer cells and initiate tumour formation. The existence of 
CSCs population poses a big challenge and limitations to standard or 
conventional cancer therapies, which tend to target the actively dividing 
cancer cells rather than the quiescent CSCs population. Hence, CSCs have 
been implicated in metastatic dissemination and cancer relapse due to 
resistance to treatment therapies (Figure 1-3). Currently, cancer research 
across academia and pharmaceutical industry focus on targeting the CSCs 
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plays important role in metastatic development by allowing cancer cells 
dissemination via the newly-formed vasculatures.  
The process of angiogenesis is summarised with the involvement of activating 
endothelial cells that trigger degradation of both basal membrane and ECM of 
surrounding cells [21]. Endothelial cells response to pro-angiogenic and anti-
angiogenic factors such as vascular endothelial growth factor (VEGF) and 
Thrombospondins respectively. The balance between pro-angiogenic and anti-
angiogenic factors thus control formation of new blood vessel [22].  
In cancer, new vasculature is formed via a phenomenon termed angiogenic 
switch, where there is an imbalance between pro-angiogenic and anti-
angiogenic factors [19]. The pro-angiogenic factors are upregulated while 
angiogenic inhibitors are downregulated in the case of cancer. Tumour cells 
can secrete pro-angiogenic factors such as VEGF, which can bind to its 
receptors (VEGFR) on the endothelial cells of pre-existing blood vessels. Such 
interaction resulted in the secretion of proteolytic enzymes including the 
matrix metalloproteinases (MMPs) to degrade the basement membrane and 
ECM. Following degradation, endothelial cells migrate towards the tumour to 
deposit a new basement membrane. Besides that, endothelial cells will secrete 
growth factors to the surrounding cells, which in turn support stabilization of 
new blood vessel at the tumour site [19]. Newly established blood vessel thus 
enables oxygen and nutrients to be delivered to the hypoxic tumour cells, 
ultimately allowing tumour growth. Many studies have demonstrated 
angiogenic factors expressed by cancer cells have an effect on endothelial cell 
growth in vitro [23]. Secreted proteins possessing angiogenic potential such as 
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the human growth hormone (hGH) [22], trefoil factors (TFFs) [24] and 
artemin [25] have also been reported to possess angiogenic potentials by 
enhancing and increasing endothelial cell growth, migration and vascular tube 
formation both in vitro and in vivo. 
1.1.1.6 Activate Invasion and Metastasis 
During the development of human cancer, primary tumour cells can acquire 
the ability to invade neighbouring tissues and metastasize to a distant site 
where they may colonize and form secondary tumours [26-28]. Metastatic 
cancers cause 90% of human cancer death due to resistance to therapeutic 
treatments and therefore many therapeutic drugs are developed to target 
metastasis [1, 28]. 
During the process of invasion, cells undergo epithelial-to-mesenchymal 
transition (EMT) where epithelial cells downregulate cell-cell interactions, 
reorganize cytoskeletons, modify cell shape and polarity, and acquire 
mesenchymal properties. Acquiring invasive capability is the first step that 
primary tumours begin to disseminate where epithelial markers (e.g. E-
CADHERIN and OCCLUDIN) are downregulated and mesenchymal markers 
(e.g. N-CADHERIN, VIMENTIN, FIBRONECTIN and SNAIL) are 
upregulated to facilitate metastasis thereafter [26].  
Metastasis is a complex multi-step process which involves local invasion, 
intravasation into lymph and/or blood vessel, survival in circulation, 
extravasation, recolonization and finally expansion [26, 28]. Upon re-
colonization, cancer cells have to undergo reverse EMT or mesenchymal-
epithelial transition (MET) to successfully reside and establish tumour growth 
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at a secondary site [27, 29, 30]. Some studies suggested that therapeutic 
strategies against EMT alone may be insufficient to target metastatic cancers. 
It should be combined with MET inhibitors for better eradication of metastatic 
tumours [26-30]. 
1.1.2 Emerging Hallmarks of Cancer 
Our knowledge and understanding on cancer biology has been enriching as 
cancer research progresses with more and more scientific findings over the 
past decades. Many of the new scientific findings have suggested emergence 
of new hallmarks in addition to the six existing ones, which together, plays 
crucial role in progression of neoplastic diseases. These emerging hallmarks of 
cancer include reprogramming of energy metabolism and evading immune 
destruction (Figure 1-4) [2].  
Both the existing and emerging hallmarks of cancer have provided a basic 
concept for understanding cancer biology. Additionally, it provided a basis for 
developing therapeutic drugs for treatment against the key hallmarks of 















Figure 1-4 Existing and emerging hallmarks of cancers (adopted with permission from 
Hanahan and Weinberg, 2011) [2]. Both existing and emerging hallmarks of cancer 
provided the basis for conceptual understanding of the complex biology of cancer. Besides 
that, many therapeutic drugs such as the EGFR inhibitors, selective anti-inflammatory drugs 
and telomerase inhibitors are developed and targeted to these hallmarks of cancer for 
treatment of various human cancers. 
1.1.2.1 Reprogramming of energy metabolism 
Normal proliferating cells utilises biosynthesis pathway such as glycolysis and 
oxidative phosphorylation to produce nutrients and energy to fuel cell growth, 
cell division and replication. Hence, metabolism of proliferating cells differ 
from cells at resting stage [31]. Similarly, cancer cells do display altered 
metabolism to meet its bioenergetics and biosynthetic demands due to the high 
rate of cell division as well as oxygen and nutrients availability.  
Most aerobic cellular organisms utilize oxidative phosphorylation for energy 
supply due to its high efficiency in releasing energy. However, cancer cells 
utilize aerobic glycolysis, a phenomenon referred as Warburg Effects [32, 33]. 
In the case of cancer, glucose breakdown from aerobic glycolysis directly 
provide cancer cells with readily available intermediates such as ribose sugar 
for generating nucleotides and amino acids. This in turn facilitates 
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biosynthesis of macromolecules such as nucleic acids, proteins and lipids 
needed to assemble new cancer cells [31]. The Adenosine Triphosphates 
(ATPs) generated during aerobic glycolysis serve as bioenergy for cancer 
cells. It is reported that the oncogene MYC can stimulate transcription of genes 
involved in mediating glycolysis pathway to fuel cancer cells [34]. Other 
pathways utilized by cancer cells include pentose phosphate pathway (PPP), 
fatty acid synthesis and glutaminolysis [1, 2, 35]. The use of PPP mainly 
generates pentoses for nucleic acid synthesis and nicotinamide adenine 
dinucleotide phosphate (NADPH) as reducing agent to prevent cancer cells 
from oxidative stress [35]. 
Cancer cells preferential usage of other alternative metabolic pathways instead 
of oxidative phosphorylation may be due to the high production of ROS by the 
latter during the generation of ATP [35]. Oxidative phosphorylation can 
generate up to a maximum of 36 ATP molecules. The higher number of ATP 
produced, the more ROS generated. Presence of ROS or by-products such as 
superoxide, peroxide and hydroxyl radicals are harmful to cell by triggering 
cellular death. Therefore, cancer cells exhibited differential or altered 
metabolic profiles so as to strike a balance to obtain sufficient bioenergy and 
biosynthesis from alternative sources and at the same time reduce oxidative 
stress that is disadvantage to its survival.  
1.1.2.2 Evading Immune Destruction 
The immune system consists of an array of cells that play important 
surveillance role in recognizing and eliminating cancer cells [1, 2]. For 
successful tumour development, dissemination and metastasis, cancer cells 
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have acquired different cellular mechanisms to avoid immune clearance. It 
have been observed that tumour biopsies heavily infiltrated with the cytotoxic 
T lymphocytes (CTL) and natural killer (NK) cells have better prognosis as 
compared to those that do not have these killer immune cells. A study has 
demonstrated cancer cells can paralyze infiltration of immune cells by 
secreting immunosuppressive factors such as transforming growth factor-beta 
(TGF-β) to dampen the immune response [36]. By doing so, cancer cells are 
able to reduce its chances in encountering immune cells and thus evade 
immune surveillance successfully. Kim et al., 2007 has also shown that 
immune-deficient mice developed carcinogen-induced tumours more 
frequently and rapidly when compared to its relative immune-competent 
control mice. In addition, the highly immunogenic cells were observed to be 
routinely eliminated in the immune-competent hosts, but formed tumours in 
the immune-deficient host [37]. Based on these studies, it appears that once 
the immune system is dampened, cancer risk increases significantly and thus 
cancer incidence becomes more common than expected. Such studies also 
highlighted the importance of tumour-host immunological interaction as it 
dictates cancer cells ability to evade immune destruction, clearance efficiency 
and form tumours. Cancer immunotherapy that uses immune system to fight 
cancer has since been successful with FDA approval of Provenge for prostate 
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embryogenesis [38]. Subsequent development is initiated during onset of 
puberty under the influence of estrogen and progesterone for ductal elongation 
and branching [14, 38]. The level of these steroid hormones varies with the 
menstrual cycle. Presence of steroid hormones alone is not sufficient to initiate 
mammary duct differentiation and maturation. Pituitary hormones such as 
growth hormone (GH) also play an important role in mammary gland 
development by stimulating the mammary stromal and epithelial cells for 
ductal elongation and differentiation [14]. This is evident in 
hypophysectomised and gonadectomised rats where treatment with estrogen 
and GH has been found to be sufficient to support puberty mammary gland 
development [40]. 
During pregnancy, ductal branching and alveoli differentiation increases 
rapidly together with an increase in adipose tissue and a richer blood flow to 
prepare the mammary gland for milk production [38]. During this phase, the 
number of myoepithelial cells also increases under the influence of steroid 
hormones, growth factors and polypeptide hormones. A few days after birth, 
lactation begins with increased prolactin (PRL) production. After weaning, the 
mammary gland undergoes regression or involution with its function and 
morphology returning to near pre-pregnancy stages where the epithelial cells 
undergo cell death. Additionally, milk glands and ducts become smaller and 
are replaced by fibrous and adipose tissue [38].  
Breast lumps including cancer develop mostly within the milk ducts and 
lobules. However, not all breast lumps are cancerous and lead to malignant 
tumour formation. For instance, presence of fibroid tissue mass or fluid-filled 
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cyst sacs is usually benign and can be common in women. The following part 
will focus on breast cancer.  
1.2.2 Breast Cancer 
Breast cancer is a complex and heterogeneous disease. It is the most common 
malignant neoplastic disease and the second leading cause of cancer death in 
women in United States of America (USA). The rate of mortality for breast 
cancer has deceased steadily due to advance in early detection, diagnosis and 
treatment. Nevertheless, an estimate of 40,000 women still die as a result of 
cancer each year due to resistance to wide variety of drugs and metastatic 
spread of cancer cells to distant organs (World Health Organisation website 
2012, http://www.who.int/mediacentre/factsheets/fs297/en/). Each year, more 
than 1400 women are estimated to be diagnosed with breast cancer, while 
more than 300 die from breast cancer in Singapore (Singapore Cancer Society 
website 2012, http://www.singaporecancersociety.org.sg/lac-gci-cancer-facts-
n-figures.shtml).  
Breast cancer originates from the cells lining the milk ducts and lobules. The 
presence of abnormal cell layer within the milk ducts and lobules is termed 
atypical ductal hyperplasia (ADH) that constitute pre-malignant lesion. The 
pre-malignant lesion stage is known as non-invasive in-situ cancer where local 
surgery to remove the abnormal cell mass is usually sufficient and patient 
usually has higher survival rate. There are the non-invasive ductal carcinoma 
in situ (DCIS) (Figure 1-6A) or the lobular carcinoma in situ (LCIS) (Figure 1-
6B), depending on the location that the abnormal cell mass is confined to. 
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organized structure of normal breast tissue is disrupted in carcinoma tissue 
sample and distinct from non-invasive, invasive and malignant breast cancer 
tissue [42]. 
Figure 1-7 Histological images of normal versus carcinoma breast tissue (adopted with 
permission from Debnath and Brugge, 2005) [42].  Histological image of normal breast 
tissue revealed a highly organized structure where the hollow lumen is surrounded by luminal 
secretory cells, which in turn is surrounded by a layer of myoepithelial and basement 
membrane. Such highly organized structure of normal breast tissue is disrupted in breast 
carcinoma tissues and is distinct between ductal/lobular non-invasive, ductal/lobular invasive 
and metastatic cancer tissues samples. For instance, invasive breast tissue samples revealed 
cells infiltrated into surrounding luminal cells, formed solid nest, poorly formed tubules and 
filling up of luminal space. 
Breast cancer can arise through familial or sporadic mutation. Familial breast 
cancer is caused by inherited gene mutation, which makes up about 5% to 
10% of all breast cancer [41]. For instance, women who have inherited gene 
mutations in Breast Cancer Susceptibility Gene 1 or 2 (BRCA1 or BRCA2) 
have an increased risk of the disease [41]. Both BRCA1 and BRCA2 play a 
role in DNA damage repair and cell cycle regulation pathways. Loss of 
function mutations of BRCA1 or BRCA2 thus greatly increases breast cancer 
risk. Genetic test is therefore highly advisable for women with strong family 
history in breast cancer. Besides that, all women are encouraged to have 
routine self-physical examination and/or mammogram screening for presence 
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of breast lump. Early detection for presence of breast lumps can greatly 
increase survival rate. Besides genetics, other risk factors for breast cancer 
also include gender, age, height, ethnic, age at menarche, age at first full term 
pregnancy, lactation, obesity and hormonal levels such as estrogens [41]. 
Taxonomy of breast cancer can be refined based on simple measures such as 
presence of predictive markers like estrogen receptor (ER), tumour grade, 
lymph node status and histological type. Based on presence of predictive 
markers, breast cancer can be divided into two distinct groups which include 
the ER-positive (ER+) and ER-negative (ER-).  This can be further sub-
classified into different tumour subtypes such as luminal A (ER+ or 
progesterone receptor-negative (PR-) and human epidermal growth factor 
receptor 2-negative (HER2-)), luminal B (ER+ or PR+ and HER2+), HER2-
positive (ER-, PR- and HER2+) and basal-like (ER-, PR- and HER2-) [43]. 
Other than that, there are different breast cancer stages (Stage 0, 1, 2, 3 and 4) 
depending on the TNM (size of tumour (T), lymph node status (N) and 
metastatic status (M)). Lymph node and metastatic status refers to whether 
there is presence of cancer cells in the lymph nodes and whether cancer cells 
have spread to a distant secondary site respectively [41]. Stage 0 of breast 
cancer refers to in-situ carcinomas such as the LCIS and DCIS where tumours 
are confined locally at the respective primary lobular and ductal site. At stage 
1-3, the tumour cells still reside within the mammary gland or regional lymph 
nodes. As disease progresses to Stage 4, tumour cells have acquired metastatic 
capability and spread to other secondary sites. Patients diagnosed with stage 3 
or 4 breast cancer have less favourable prognostic outcome. These different 
classification or taxonomy categorise breast cancer into different criteria and 
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characteristics that can help doctors dictate the appropriate treatments, predict 
survival outcome and prognosis for the patients. 
Current treatment of breast cancer includes local surgery, radiotherapy, 
chemotherapy and hormonal therapy. For instance, early stage breast cancer 
patients diagnosed with small primary tumours are usually treated with local 
surgery to remove the tumours and subsequently radiotherapy to eradicate 
residual cancer cells that might not be removed via surgery. Chemotherapeutic 
drugs can also be used to eliminate tumour cells which have metastasized from 
the primary tumour or locally advanced stage cancer [44]. Currently, the most 
common chemotherapeutic drugs used for breast cancer in clinics includes 
alkylating / crosslinking agents (e.g. cyclophosphamide), anthracyclines (e.g. 
doxorubicin) and anti-microtubule agents (e.g. paclitaxel) [45]. Hormonal 
therapy currently available includes anti-ER therapies (e.g. tamoxifen and 
fulvestrant) and aromatase inhibitors (e.g. letrozole; anastrozole; exemestane). 
Breast cancer patients diagnosed with lymph node-positive disease where 
malignant cells have invaded surrounding lymph node and/or blood vessels, 
usually have a high risk of local recurrence as well as systemic recurrence. A 
combination of treatment (surgery with radiotherapy, chemotherapy and/or 
hormonal therapy) will thus be useful for better eradication of the tumour cells 
and improve overall survival outcome as well as reduce disease relapse.  
In some cases, multigene testing is often performed on breast tumours so as to 
determine combination of therapies (i.e. hormonal and chemotherapy) that 
might most benefits breast cancer patients [46]. The challenge here will be to 
administer chemotherapeutic drugs at a dosage that maximizes its efficacy, 
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and at the same time, minimize its toxicity in patient. Despite the benefits that 
various therapeutics can offer in targeting cancer cells, de novo existence or 
acquisition of resistance to treatment or relapse still remains an obstacle 
clinically [46, 47]. It is therefore of importance to investigate and understand 
pathways responsible for resistance as this will provide clues on mechanisms 
of resistance to various treatments.  
1.2.3 HER2+ breast cancer 
The Human Epidermal Growth Factor Receptor 2-positive (HER2+) breast 
cancer is associated with frequent amplification of the HER2/neu gene, which 
is located at chromosome 17q12-q21.1 [48-51]. It is well studied that over-
expression of HER2 plays a critical role in the development of mammary 
malignancies and is seen in up to 25-30% of breast cancers [48, 49, 52, 53]. It 
is often associated with an aggressive phenotype where patients diagnosed 
with HER2+ breast cancer usually have increased risk of disease progression, 
higher tumour relapse and poorer prognosis as compared to HER2/neu-
negative breast cancer patients  [8, 54, 55] .  
1.2.3.1 HER2 and its Function 
The HER2 belongs to the human epidermal growth factor receptor 
(EGFR/ErbB/HER) family. This family of receptor tyrosine kinases (RTKs) 
have been involved in the development of many types of cancers including 
breast, ovarian and gastric [7, 53, 56, 57]. In this family, there are four 
identified members that include the epidermal growth factor receptor (EGFR, 
also known as HER1), HER2, HER3 and HER4 (Figure 1-8) [53]. The genes 
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All members and its respective ligands are essential and expressed during 
normal development and maturation of the mammary gland [60]. The EGFR 
plays a function in promoting ductal growth, while HER2 and HER4 are 
involved in lobuloalveolar differentiation as well as lactation. Among the 
members, EGFR and HER2 are commonly deregulated in certain prevalent 
forms of human cancers where overexpression or mutated forms of these 
proteins were demonstrated to trigger malignant transformation [58, 60, 61]. 
1.2.3.2 HER-mediated Signal Transduction 
When ligand binds, the receptors undergo conformational changes that allow 
homo-dimerization (e.g. HER1-HER1; HER2-HER2, HER3-HER3 and 
HER4-HER4) or hetero-dimerization (e.g. HER1-HER2; HER2-HER3; 
HER2-HER4) of the receptors [53, 55]. Dimerization results in transactivation 
and subsequent phosphorylation of its cytoplasmic tyrosine residues, which in 
turn serves as recognition sites for an array of adaptors and other 
phosphotyrosine-containing intracellular signalling molecules to rely signals 
downstream (Figure 1-8) [8, 59]. Signalling molecules such as Src homology 
2/α collagen-related (Shc) protein, Signal Transducer and Activator of 
Transcription 5 (STAT5) and Growth Factor Receptor Bound 2 (Grb2) then 
relies signal downstream and activate survival or proliferation pathways such 
as mitogen activated protein kinase (MAPK), phosphatidylinositol-3 kinase- 
anti-apoptotic serine/threonine kinase (PI3K-Akt) and nuclear factor κB 
(NFκB) [7, 8, 55, 57]. Among the members, HER1 and HER4 have greater 
diversity of phosphotyrosine interacting partners than HER2 and HER3 
(Figure 1-8). Phosphorylation of different cytoplasmic tyrosine residues is 
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reportedly related to activation of defined downstream intracellular signalling 
pathways [7, 59].  
The HER signalling network is highly complex, robust and diverse due to the 
different possible combinations of receptor dimers (e.g. HER1-HER1; HER1-
HER2; HER2-HER2; HER2-HER3; HER3-HER3; HER2-HER4 and HER4-
HER4) (Figure 1-9). Dimerization pairs that include HER2 have been found to 
be more stable and cause more potent signalling compared to dimerization 
pairs without HER2 [53].  Also, dimers formation is highly dependent on the 
respective expression levels of each HER receptors. Importantly, receptor 
heterodimerization triggers the intrinsic tyrosine kinase activity of each 
receptor in the pair that permits the recruitment of different complements of 
phosphotyrosine-containing signalling molecules at the cytoplasmic tails. 
Therefore, further diversifies the repertoire of signalling pathways that can be 
activated [53]. The HER signalling has also been described as a redundant 
network as the system involves many positive and negative feedback 
regulatory mechanisms that protects it from various perturbation, a feature 

















Figure 1-9 Overview of the HER signalling pathway (Illustration reproduced courtesy of 
Cell Signaling Technology. Inc. (www.cellsignal.om. <http://www.cellsignal.com/>). It 
illustrated the signalling molecules involved for activation of cellular activities such as cell 
differentiation, proliferation, growth and chemotaxis.  
1.2.3.3 HER2-mediated mammary carcinoma 
The HER members can activate a multitude of signalling pathways that govern 
many aspects of cellular function such as cell growth, proliferation, survival, 
differentiation and motility. Deregulation and/or overexpression of any HER 
members can thus potentially contribute to uncontrolled cell growth and 
promote survival that can lead to formation of tumour. Indeed, studies have 
shown frequent mutation and/or overexpression of HER family members in a 
number of human cancers. Among all members, the EGFR and HER2 have 
been demonstrated to play the most significant role in cancer.  
Research studies have consistently observed that amplification of the 
HER2/neu gene promotes proliferation, angiogenesis, enhances invasive and 
metastatic potential in cancers such as breast, ovarian and colorectal cancers 
28 
 
[57]. Overexpression of HER2 has been reported to correlates with larger 
tumour size and spread of tumour to lymph nodes. Since HER2 often acts as 
coreceptor, overexpression of HER2 can result in spontaneous formation and 
constitutive ligand-independent dimerization of HER2 homodimers, 
EGFR/HER2 and HER2/HER3 heterodimers with subsequent activation of its 
receptors cytoplasmic kinase region (Figure 1-10) [52, 63]. Existence of HER2 
homodimers can form complex with partition protein 6 (Par6) and atypical 
protein kinase C (aPKC) resulting in the loss of cell polarity, disruption of 
tight junction and inhibition of apoptosis that can enhance EMT, cell 
migratory potential and survival [48, 52]. An increase of EGFR/HER2 
heterodimers will result in an increased downstream signalling through 
Ras/Raf/MAPK pathway, which in turn upregulates Cyclin D1 and 
subsequently enhances cell cycle progression [52]. The pairing between HER2 
and HER3 is thought to trigger the strongest signalling of all receptor 
combination. Presence of high numbers of HER2/HER3 heterodimers on cell 
surface enhances cell survival via activation of P13K/Akt pathway [52]. 
Therefore, enhanced expression of HER2 confers a strong proliferative and 
survival advantages for tumour cells. It is thus evident that overexpression of 













Figure 1-10 Signalling pathways activated in the presence of HER2 overexpression 
(adopted with permission from Kruser and Wheeler, 2010) [52]. Overexpression of HER2 
resulted in increased formation of HER1/HER2 heterodimers, HER2/HER2 homodimers and 
HER2/HER3 heterodimers, which ultimately enhances activation of proliferation and survival 
pathways. 
1.2.3.4 HER2+ Breast Cancer Treatment  
There have been different therapies developed to treat HER2+ breast cancer, 
all of which involved interfering the HER pathway to stop the cascade of 
signals that leads to cell growth and survival. Current treatment for HER2+ 
breast cancer include the use of Trastuzumab (Herceptin), Lapatinib, 
Pertuzumab and Trastuzumab emtansine (TDM-1), which are therapeutic 
drugs approved by the US Food and Drug Administration (FDA) (Figure 1-11) 
[64]. 
Trastuzumab or Herceptin (Genentech Inc., San Francisco, CA) is the first 
FDA-approved therapeutic drugs developed for treating HER2+ metastatic 
breast cancer patients and also in adjuvant setting for HER2+ breast cancer 
treatment [64, 65]. It is a recombinant monoclonal antibody targeting the 
extracellular segment (domain 4) of HER2 [52]. Herceptin binding to HER2 
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induces antibody-dependent cell-mediated cytotoxicity (ADCC), thereby 
resulting in the disruption of HER [66]. Herceptin-targeted cells exhibited 
reduction in proliferation and tumour growth in vitro and in vivo as it 
undergoes cell cycle arrest at G1 phase [65]. Herceptin can either be 
administered alone or in combination with chemotherapy after disease 
progression and resistance have been reported in Herceptin-based therapy 
[67]. Combination therapy is now often used as a standard first-line treatment 
for HER2+ metastatic breast cancer patients [52]. The levels of HER2 are 
either absent or low in most normal tissues except the heart. Therefore, 
Herceptin-treated breast cancer patients could suffer from cardiovascular side 
effects [57]. Besides that, this monoclonal antibody lacks action on brain 
metastases due to blood-brain barrier (BBB). 
New or improved therapies have been developed for HER2+ breast cancer 
patients whose disease progresses and relapses on Herceptin to improve 
survival and also minimize treatment-related toxicity. Lapatinib, pertuzumab 
and trastuzumab emtansine (TDM-1) are the new therapeutic options approved 
by FDA for treating patients facing Herceptin-refractory metastatic breast 
cancer.  
Lapatinib (Tyverb/Tykerb) is a tyrosine kinase inhibitor (TKI) targeting both 
EGFR/HER1 and HER2 [49, 68]. Lapatinib mode of action is to compete with 
ATP binding site at the intracellular tyrosine kinase domain of EGFR and 
HER2, prevent phosphorylation of cytoplasmic tail and thus abrogate 
activation of downstream signalling pathways that are involved in cell 
proliferation and survival (Figure 1-11) [64, 65, 67, 69]. It is often used in 
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combination with either endocrine therapy (e.g. letrozole) or capecitabine for 
advanced HER2+ breast cancer patients in cases where chemotherapy and 
Herceptin fails [49]. Unlike Herceptin, Lapatinib is able to carry out its 
activity for central nervous system (CNS) metastases in HER2+ breast cancer 
patients due to its small molecular size that may cross the BBB to provide 
effective action in the cerebrospinal fluid [49]. Besides that, Lapatinib is 
reportedly to be associated with less cardiotoxicity. HER2-targeted therapy 
involving the use of Lapatinib have shown high efficacy in HER2+ breast 
cancer patients, however resistance to this drug is reportedly prevalent [62].  
Pertuzumab is a humanized monoclonal antibody that targets the extracellular 
part of HER2 at Domain 2, which is essential for receptor dimerization. 
Binding to this domain of the receptor efficiently creates steric hindrance that 
blocks ligand-induced homo- and heterodimerization in particularly HER2-
HER3, thereby inhibiting downstream signalling pathways such as MAPK and 
PI3K-Akt and ultimately tumour growth [68, 70, 71]. One difference between 
Pertuzumab and Herceptin is that the latter have minor effect in the presence 
of ligand as it binds to different extracellular domain on HER2 [70, 71]. Since 
Pertuzumab and Herceptin binds to HER2 at different domain, the mode of 
action of Pertuzumab is complementary to that of Herceptin. For instance, 
preclinical and clinical studies have demonstrated a more comprehensive 
blockage of HER2-driven signalling pathway when the pertuzumab-mediated 
HER2 dimerization inhibition and anti-HER2 activity of Herceptin is 
combined than either agent alone [66, 72, 73] . This synergistic anti-tumour 
activity resulted in FDA-approval of pertuzumab to be used and combined 
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1.2.3.5 Intrinsic and Acquired Resistance in HER2+ Breast Cancer 
Treatment 
Despite the benefit of Herceptin in treating HER2+ breast cancer patients, 
intrinsic and acquired resistance have progressively been recognized as a 
major limitation in current HER2+ breast cancer treatment [52, 71]. The 
duration of patients’ response to Herceptin alone or in combination with other 
chemotherapeutic drugs have been reported to range from 5 to 9 months, 
implicating that acquired resistance often develops [50, 52, 74].  Neve et al., 
2006 assessed growth inhibition responses of nine HER2-amplified cell lines 
to Herceptin and found only three out of nine exhibited robust response to the 
drug as measured by inhibition of BrdU incorporation [75].  This is in line 
with clinical reports where approximately 35% patients receiving Herceptin 
alone are responsive to the drug, while others do not respond clinically [50, 
60, 75]. Besides that, patients who show primary response were found to 
develop resistance to Herceptin eventually and disease progresses within one 
year of treatment [49, 52]. Gene expression analysis suggested that 
upregulation of genes involved in insulin/MAPK predicts response to 
Herceptin, whereas the mammalian target of rapamycin (mTOR) and Toll-like 
receptor pathways associate with Herceptin resistance [75]. However, there are 
no conclusive biomarker(s) for patient responsiveness to Herceptin. Therefore, 
there is a need to identify molecular features that may allow more precise 
identification of HER2+ breast cancer patients’ responsiveness to therapeutic 
protocols containing Herceptin.  
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One of the mechanisms of resistance to Herceptin is mutation to the target 
itself particularly at the HER2 domain that contains the binding epitope for 
Herceptin. This can cause direct steric hindrance or restriction to 
conformational flexibility that impairs receptor-antibody binding and thus 
renders Herceptin efficiency to block cell cycle arrest [76].  
Another proposed mechanism of resistance to Herceptin is the presence of a 
truncated form of HER2 (p95-HER2) in the circulation that arises from 
alternative transcription of HER2. The N-terminal of p95-HER2 retains the 
constitutively active kinase that can potentially dimerize with other HER 
members and allow activation of the respective downstream signalling 
pathways. Unlike HER2, the Herceptin-binding region is absent in p95-HER2, 
which enables activated signalling even in the presence of Herceptin. 
Therefore, p95-HER2 is demonstrated to be susceptible to lapatinib inhibition 
but not Herceptin [63, 74, 76, 77]. It is reported that among the HER2-
amplified breast cancers, 30% of which displayed expression of the truncated 
p95-HER2 and is associated with shorter disease-free survival when compared 
with tumours that overexpress the full length HER2 [74]. In both in vitro and 
in vivo studies, cell lines and xenograft models transfected with the truncated 
HER2 displayed resistance to Herceptin [78, 79].  
The loss of phosphatase and tensin homolog (PTEN) via mutational 
inactivation or downregulation of expression has also been reported to be 
strongly correlated with Herceptin resistance. The absence of PTEN results in 
constitutive activation of PI3K-Akt signalling pathway that drives aberrant cell 
growth and proliferation in HER2-amplified breast cancer cells, which is also 
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observed in other tumour types [80]. Furthermore, upregulation of PI3K-Akt 
signalling through mutational activation of the catalytic subunit of PI3K 
(PI3KCA) has been implicated in resistance of HER2+ breast cancer to 
Herceptin [81]. 
The ability of HER2 to form heterodimers with other extracellular HER 
members (HER1 and HER3) can result in incomplete inhibition by Herceptin 
through lateral activation of alternative pathways mediated via HER1 or HER3 
[52, 82]. Cross talk between HER2 and other receptors also provides 
alternative proliferative and survival stimuli for growth-promoting effects to 
the tumour even in the presence of effective inhibition of the HER pathways. 
For instance, it is reported that GH is able to stimulate phosphorylation of 
EGFR/HER1 at Tyr1068 site via Janus Kinase 2 (JAK2) and elicit activation 
of MAPK pathway that is independent of the intrinsic kinase activity of 
EGFR/HER1 [83]. Besides that, formation of HER2-insulin growth factor-1 
receptor (IGF-1R) heterodimers was observed to phosphorylate and activate 
HER2 by IGF1-like ligands in Herceptin-resistant cells [84]. Another research 
group from Japan have reported that in human breast cancer cell line, 
autocrine secretion of prolactin resulted in constitutive tyrosine 
phosphorylation of HER2 (Tyr1139) via the JAK2 kinase, thus providing a 
docking site for stimulation of Ras-MAPK cascade and causing unrestricted 
proliferation [85].  
The findings of these studies suggested additional levels of complexity in 
Herceptin-acquired resistance and demonstrated that blocking of one 
molecular target (HER2) may still allow an escape via alternate signalling 
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cascades. The different mechanisms of resistance to Herceptin also indicated 
cancer cells ability to continuously adapt to different signalling pathways as a 
strategy for survival and growth.  
Although Lapatinib has been proven to be effective in clinical trials, majority 
of patients who are Lapatinib-responsive eventually become resistant to this 
drug. Moreover, most of the patients pre-treated with Herceptin failed to 
respond to Lapatinib thereafter as well, on an average in less than a year [86]. 
It has been proposed that the major mechanism of resistance to lapatinib is 
through activation of compensatory survival pathways [66].  
It is becoming clear that HER2 expression status alone is not adequate as 
predictive marker to predict response to HER2-targeted therapy including 
Herceptin. There is therefore a need to define the characteristics, identify 
additional markers and the molecular mechanism of therapeutic resistance in 
HER2+ mammary carcinoma so as to better design combination therapy, 
develop more effective HER2 targeting drugs or even tailor the treatment 
accordingly for HER2+ subtype breast cancer patients.   
1.3 Human Growth Hormone (hGH) 
1.3.1 Growth Hormone and its Function 
The growth hormone (GH) is a secreted peptide hormone whose classically 
descried biological function is to stimulate longitudinal growth, cell 
proliferation, differentiation, survival and regeneration [87, 88]. It belongs to a 
class of evolutionarily related hormonal proteins that include prolactin (PRL) 
and placental lactogens (PL) [88]. In human, the gene encoding GH (hGH) is 
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located on the long arm of chromosome 17 (17q22-24) [89]. The hGH gene 
belongs to a gene cluster that consists of 5 closely related genes, namely the 
GH-N (GH-normal gene), the GH-V (GH-variant gene), the CS-L (chorionic 
somatomammotropin-like gene), the CS-A (chorionic somatomammotropin-A 
gene), and the CS-B (chorionic somatomammotropin-B gene) (Figure 1-12).  
The GH-N (GH1) is the predominant circulating human growth hormone 
(hGH) in children and adult. Proteolytic processing of GH-N gives rise to a 22 
kDa, 191 amino acids peptide that is found predominantly in plasma. 
Alternative splicing of the GH-N mRNA produces a smaller 20 kDa isoform 
protein that represents 5-10% of monomeric hGH in the pituitary [88]. The 
GH-V (GH2) is expressed only in the placenta and present in maternal serum 
during the late stage of pregnancy.  The CS-L, CS-A and CS-B are also 
referred as placenta lactogen genes [88, 89]. Like GH-V, CS-A and CS-B 
genes are expressed in human placenta and all play a role during growth of 
fetus and lactogenesis. The CS-L gene is a pseudogene that does not produce a 
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cause the receptors to either homodimerize or heterodimerize, leading to its 
activation [94]. Ligand binding are thought to stabilize GHR-JAK2 complex, 
allowing two JAK molecules to come closely in proximity to phosphorylate 
each other [88, 93]. The activated JAK2 in turn phosphorylate multiple 
intracellular tyrosine residues that serve as docking sites for a variety of 
cytoplasmic adaptors and other signalling molecules containing SH2 or 
phosphotyrosine-binding (PTB) motifs to transduce signal downstream [92]. 
The Shc protein, signal transducer and activator transcription factor 1, 3 and 5 
(STAT1, STAT3 and STAT5), phosphoinositide-3 (PI-3) kinase and 
phospholipase C (PLC), focal adhesion kinase (FAK) are some examples of 
signalling molecules recruited by GH stimulation [88, 95]. Once bound to 
GHR, these signalling molecules are rapidly phosphorylated and activated by 
JAK2. For instance, the activated and phosphorylated STAT1, STAT3 and 
STAT5 translocate to the nucleus, bind to DNA and activate target gene 
expression. The phosphorylated Shc protein can interact with and 
phosphorylate Grb2, which in turn activates Ras-Mitogen Activated Protein 
Kinase (RAS-RAF-MEK-MAPK) pathway [88]. The MAPK pathway has a 
pivotal role in regulating of gene transcription, cell proliferation and 
preventing apoptosis. GH stimulation also activates other signalling pathways 
such as PI3K-Akt [92]. 
Predominantly, GH utilizes JAK2 to elicit physiological pathways that 
stimulates growth, survival and proliferation [88]. Other studies have also 
shown that GH can recruit JAK1 [96] and other phosphotyrosine kinases (e.g. 
Src) [97] to rely and transduce GH-mediated signal downstream. Like GHR, 
PRLR also utilises JAK2 tyrosine kinase to rely GH-mediated signal 
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transduction into the nucleus for target gene expression [98]. Both PRLR and 
GHR have been reported to activate very similar signalling pathways such as 
Ras-Raf-MEK-MAPK and PI3K [98]. Since GH can bind to both GHR and 
PRLR, crosstalk between the two signalling pathways has been reported 
during GH stimulation [92].  
GH stimulation resembles a bell-shaped curve. In other word, when 
concentration of GH is high, the higher affinity receptor site 1 will be 
saturated. This prevents receptor dimerization via the low affinity binding site 
2, thereby creating a self-antagonistic effect for GH receptor activation [92]. 
Also, high concentration of the hormone induces homologous downregulation 
of receptor expression [99].  
1.3.4 Growth Hormone-Related Disorder(s) 
Given that GH plays important role in regulating somatic growth, cellular 
proliferation, differentiation and survival, abnormal GH levels may thus result 
in pathological conditions.  
Hyposecretion of GH from pituitary during childhood can result in dwarfism. 
One feature that is observed in people suffering from dwarfism or sometimes 
known as “little people” is short statues or stunted growth due to GH 
deficiency [100]. The FDA has approved the use of recombinant hGH (rhGH) 
as the prescription drug to treat dwarfism and other childhood or adult growth 
deficiencies [101]. Interestingly, there have been studies showing an 
association between growth hormone deficiencies with protection from cancer. 
For instance, Guevara-Aquirre J et al., (2011) reported that people who 
suffered from congenital GHR deficiency known as Laron Syndrome, 
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exhibited major decline in the incidence of cancer, diabetes as well as pro-
aging signalling [102]. In their study, 100 Ecuadorian Laron subjects and 1600 
individuals of normal status were monitored over a period of 22 years where 
no diabetes case and only one non-fatal cancer event in the Laron’s subjects 
was observed. In contrast, the incidence of cancer and diabetes were found to 
be 17% and 5% respectively in the control subjects. Besides that, an animal 
model study done using the spontaneous dwarf rat that contains autosomal 
recessive mutation in the GH gene was observed to exhibit significant 
reduction in chemically-induced carcinogenesis including cancer formation in 
the breast due to the absence of functional serum GH [103].  
Hypersecretion of GH during childhood can lead to gigantism where children 
display significant height above average. Besides that, excessive GH secretion 
from anterior pituitary after epiphyseal plate closure at puberty can result in 
acromegaly in adult [104]. This is evident in animal model study where 
acromegaly was observed in transgenic rabbits with GH overexpression [105]. 
Gigantic or acromegalic conditions produce enlarged bones, especially in the 
face, and also results in organomegaly and is associated with increased 
morbidity and mortality due to cardiovascular, metabolic and respiratory 
diseases. Furthermore, epidemiological studies of acromegalic patients 
indicate an increased in cancer risk such as benign and malignant tumours of 
the colon, breast, prostate and thyroid [104]. Somatostatin analogs and 
dopamine agonist have been utilized for gigantism and acromegaly treatment 
by suppressing GH, thereby controlling its secretion and action. Moreover, a 
GHR-specific antagonist B2036, has been useful for treating disorders linked 
to excessive hGH, including gigantism and acromegaly [106]. The molecular 
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structure of B2036 contains eight amino acid substitutions that are 
advantageous to its action as the affinity of binding site 1 to GHR is greatly 
improved. Additionally, it has a single amino acid substitution (glycine Æ 
lysine) that impair receptor binding site 2 (G120K), thereby abrogating the 
necessary conformational change required for functional GHR dimerization 
and subsequent signal transduction (Figure 1-15B) [107, 108]. Maamra et al., 
1999 have demonstrated B2036 prevents GHR-mediated JAK2 
phosphorylation and STAT5 signalling [109]. Like the dimerized GH-GHR 
complex, B2036-GHR complex is rapidly internalised, which reduces its drug 
efficacy. Nevertheless, rapid internalisation can be overcame by conjugating 
four to five moieties of polyethyl glycol (PEG) to B2036 that generate a higher 
molecular weight molecule termed pegvisomant (Figure 1-15C) [107]. The 
increase in molecular weight also effectively prolonged pegvisomant half-life 
from body clearance, thereby making it the first clinically efficacious GHR 
antagonist for acromegaly treatment. Though pegvisomant have reduced 
antagonistic activity than its unpegylated form due to steric hindrance induced 
by PEG addition, high concentration is sufficient to completely block GH 
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post-menopausal breast cancer respectively [114]. These few studies described 
here are among the many epidemiological evidences that highlighted or 
supported the association between risk of cancer and greater height in both 
childhood and adulthood. However, the mechanism involved in such 
epidemiological observation is still unclear.  
The next sub-section of this introductory part of the thesis will discuss the role 
of hGH in mammary neoplasia progression as well as the functional pathways 
on how deregulation of hGH is linked to breast cancer.  
1.3.5 Autocrine hGH in Mammary Neoplasia and Breast Cancer 
The involvement of pituitary hormone in pathogenesis of breast cancer is 
observed where there is dramatic regression of mammary tumour following 
the removal of pituitary gland or hypophysectomy. Subsequent to this 
observation, hypophysectomy was employed as therapy for breast cancer in 
the 1950s [115].  
Most recent researches have revealed accumulating numbers of evidence 
demonstrating the importance of autocrine hGH in development and 
progression of tumours of the female reproductive system, hence giving rise to 
cancers of the breast [14], endometrium and ovary observed in cell line 
models, animal models and clinical settings [116].  
Autocrine hGH can produce different growth related effects to endocrine GH. 
The endocrine GH is secreted from anterior pituitary in a pulsatile fashion. It 
enters blood circulation and act on numerous target tissues for somatic growth. 
In contrast, autocrine hGH is secreted continuously and have been indicated as 
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an oncogene in driving mammary neoplasia development and progression by 
promoting cell survival, proliferation [95], immortalization, inducing 
angiogenesis [22], EMT [117] and enhancing metastasis [14, 118, 119]. The 
studies for these observations are discussed here. 
Acquiring the ability to overcome anti-proliferative regulation and resist 
apoptosis is one of the key step in oncogenic progression, which is observed in 
the presence of autocrine hGH. Forced expression of the hGH gene in non-
invasive mammary carcinoma cell line, MCF7 resulted in an upregulation of 
C/EBP homologues protein (CHOP) in a p38 MAP kinase-dependent manner 
[119]. Cell proliferation increased significantly when CHOP is upregulated. 
Concomitantly, the hGH-overexpressing MCF7 cells exhibited decreased 
apoptotic events. In the same study, usage of specific GHR antagonist B2036 
abrogated the increased cell growth and protection against apoptosis. 
Additionally, B2036 effectively inhibited autocrine hGH-induced activation of 
JAK2/STAT5, CHOP (p38 MAPK) and Elk-1 (p44/42 MAPK) pathways 
[119]. Autocrine production of hGH also upregulated expression of homeobox 
containing gene (homeobox A1 (HOXA1)), a potent mammary oncogene that 
transcriptionally regulate expression of other genes such as c-myc, cyclin D1 
and Bcl-2. Together, these genes drive oncogenic transformation of mammary 
carcinoma cells by increasing proliferation, survival and opposing apoptosis 
[120]. 
Limitless replicative potential is achieved by autocrine hGH-mediated 
upregulation of poly(C)-binding protein (αCP1) that stabilises the telomerase 
catalytic subunit (human telomerase reverse transcriptase (hTERT)) mRNA 
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resulting in increased hTERT expression at both transcript and protein levels. 
The increased hTERT expression in turn increases telomerase activity and 
extends replicative potential of normal human mammary epithelial cells 
(HMEC) [121]. Additionally, Zhu et al., (2005) demonstrated forced 
expression of hGH in a normal, but immortalized human mammary epithelial 
cells (MCF10A) stimulated oncogenic transformation of these cells with 
subsequent tumour growth and formation in xenograft model through 
increased cell proliferation and survival [122]. The in vitro data shown in the 
same study revealed autocrine expression of hGH have the ability to enhance 
anchorage-independent growth in JAK2-dependent manner. Subsequent 
treatment of hGH-transfected MCF10A and MCF12A immortalized cells with 
JAK2-specific inhibitor (AG490) abrogated the cells ability to growth and 
form colony in culture.  
The inner environment of tumour mass is often challenged with nutrients and 
oxygen availability or hypoxia. Therefore, cancer cells exhibit angiogenic 
switch to create new vasculature that transport nutrients and provide oxygen to 
the tumour mass. A study conducted by Brunet-Dunand et al., 2009 reported 
that autocrine production of hGH exhibits oncogenic ability that enhances 
angiogenic potential of MCF7 mammary carcinoma cells in VEGF-A 
dependent manner [22]. The increase expression of pro-angiogenic VEGF-A 
factor in hGH-overexpressing MCF7 cells promoted human microvascular 
endothelial cell (HMEC-1) tube formation in vitro. Induction of tube forming 
is abrogated in the presence of both the VEGF-A inhibitor (bevacizumab) and 
GHR-specific antagonist (B2036). Injection of MCF7-hGH overexpression 
cells into the auxiliary mammary fat pad of nude mice increases microvessel 
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density and stimulates tumour angiogenesis and lymphangiogenesis as 
compared to its relative nude mice injected with control cells. The in vitro and 
in vivo data clearly indicated autocrine hGH as a potential regulator of tumour 
neovascularization, angiogenesis and lymphangiogensis, which consequently 
provides a favourable survival advantage for the cancer cells to progress to the 
next stage of cancer that is invasion and migration where cancer cells begin to 
gain entry into blood and lymph node, followed by tumour metastasis to a 
distant site. 
Before metastasis can occur, cancer cells have to undergo morphological 
changes from a polarized epithelial state to mesenchymal morphology such as 
loosening of tight junctions in order to be “mobile” for invasion and migration. 
Autocrine production of hGH in MCF7 cells has been shown to upregulate 
mesenchymal markers (VIMENTIN), and downregulate epithelial markers and 
tight-junction molecules (E-CADHERIN, α- and γ-CADHERIN, OCCLUDIN 
and PLAKGLOBIN) [117]. Also, closing up of artificial wound inflicted on 
monolayer of hGH-overexpressing MCF7 cells was significantly more rapid 
than its relative control cells. The increased in cell motility and local invasion 
of MCF7 cells were due to autocrine hGH-mediated upregulation of matrix 
metalloproteinases, MMP2 and MMP9, which function to degrade ECM. Tail 
vein injection of MCF7-Vec and MCF7-hGH cells into immunodeficient mice 
demonstrated that forced expression of hGH in MCF7 cells promoted lung 
metastases [22]. Here, it evidently showed the oncogenic role of autocrine 
hGH in mediating EMT, invasion, migration and metastasis in ER+ mammary 
carcinoma in vitro and in vivo [22, 117]. Besides that, autocrine hGH is able to 
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mediate oncogenesis and increase malignant transformation of normal 
mammary epithelial cells.  
Drug resistance is increasingly recognized as the main cause of chemotherapy 
failure observed in cancer patients with metastatic disease, including breast 
cancer. There are increasing evidence indicating that autocrine hGH not only 
plays a role in oncogenic transformation and progression of breast cancer, but 
also confers resistance to multiple classes of chemotherapeutic agents used in 
breast cancer treatment, including doxorubicin [120], tamoxifen [123] and 
mitomycin C (MMC) [124]. Additionally, Bougen et al., 2012 reported the 
contribution of autocrine hGH in radioresistance observed in ER+ breast 
cancer as well as endometrial cancer in their in vitro and in vivo studies [125]. 
These chemo- and radioresistance studies demonstrated that following drugs 
or ionising radiation (IR) exposure, hGH-overexpressing mammary carcinoma 
cells still exhibited enhancement in cell viability, clonogenic survival, 
anchorage-independent growth in soft agar and cell transformation in 3D when 
compared to its relative control-treated and untreated cells. Concordantly, 
there is a reduction in drugs-induced apoptotic cell death or IR-induced DNA 
damage in mammary carcinoma cells that are stably transfected with hGH 
gene. Functional inhibition of hGH using B2036 is shown to re-sensitize these 
mammary carcinoma cells to chemotherapeutic drugs or IR treatment [120, 
123-125].  
Based on the studies discussed above, Perry et al., 2006 identified and 
concluded that autocrine and/or paracrine action of hGH is capable of 
activating an array of signalling pathways (e.g. JAK2-STAT3, JAK2-STAT5, 
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PI3K, c-Src and ERK) that are involved in cell proliferation, survival, motility 
and angiogenesis in order to provide pro-survival advantage to drive abnormal 
growth of tumour mass and tumour malignancy (Figure 1-16). Autocrine 
and/or paracrine expression of hGH can thus generate a platform for 
oncogenic manifestation observed in ER+ mammary carcinoma [95]. Also, 
these observation is exclusively mediated by autocrine production of hGH as 
addition of exogenous hGH to mammary epithelial cells in culture to mimic 
pituitary derived hGH, does not exert effects in oncogenic transformation of 






Figure 1-16 Autocrine hGH-mediated signal transduction in human mammary epithelial 
cells (adopted with permission from Perry et al., 2006) [95]. Autocrine hGH is reported to 
up-regulate telomerase activity, oncogenic transformation, epithelial to mesenchymal 
transition and chemoresistance, which together provided a platform for oncogenic 
transformation in breast cancer. 
Subsequent microarray analysis conducted by Xu et al., 2005 identified 305 
genes that are differentially expressed in MCF7 cell line in response to 
autocrine hGH, as well as exogenous hGH [126]. Among these identified 
genes, IGF-1, trefoil factor 1 and 3 (TFF1 and TFF3), bone morphogenic 
protein-7 (BMP-7) are some examples of genes found to be upregulated by 
autocrine hGH. These soluble proteins are capable of enhancing cell survival 
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and proliferation that eventually generate tumour formation. For instance, 
elevated IGF-1 level is well reported to induce hyperplasia lesions leading to 
tumourigenesis and associated with increased risk of breast, colorectal and 
prostate cancers [127]. Functional characterization of the trefoil factor (TFF1 
and TFF3) family revealed that these soluble secretory proteins are capable of 
increasing cell survival, tumour formation and protection against apoptosis in 
breast cancer in vitro and in vivo [128, 129]. The same microarray data also 
revealed genes that are downregulated in response to autocrine expression of 
hGH such as the thrombospondin-1 (Tsp1), a known inhibitor of angiogenesis 
[130]. Therefore, autocrine expression of hGH in human mammary epithelial 
cells can stimulate upregulation of a number of secreted proteins that are 
capable of generating multiple autocrine and/or paracrine loops, thereby 







Figure 1-17 Oncogenic potential of autocrine hGH acting in autocrine and paracrine 
(adopted with permission from Perry et al., 2006) [95]. Autocrine hGH upregulate soluble 
peptide factors, which include insulin-like growth factor-1 (IGF-1) and trefoil factor 1 and 3 




All the studies provided a suggestive indication that autocrine expression of 
hGH to be relevant for disease progression. In accordance, Chiesa J et al., 
(2011) reported the proliferative effects of autocrine hGH is maintained in 
primary human mammary carcinoma cells (HMCC) that is derived surgically 
from biopsies of patients diagnosed with mammary carcinoma [131]. It 
revealed elevated expression of hGH and its receptor (hGHR) in HMCC at 
both transcript and protein levels, as well as the extracellularly secreted hGH. 
Both hGH-positive and negative HMCC proliferated more rapidly in presence 
of exogenous hGH. However, decreased proliferation is only observed in 
hGH-positive HMCC when hGH was antagonised by B0236. 
A clinical study conducted by Wu et al., 2011 on a cohort of 159 breast cancer 
patients and 33 benign breast disease patients demonstrated that tumour 
expression of hGH at both transcript and protein levels were significantly 
associated with clinicopathologic parameters including lymph node metastases 
(LNM), higher tumour stage, tumour grade, HER-2 status and proliferative 
index in mammary and endometrial carcinomas [132]. This study also looked 
at tumour expression of hPRL in both mammary and endometrial carcinomas. 
Presence of tumour expression of hPRL at both transcript and protein levels 
are also reported to be significantly associated with LNM, tumour grade and 
tumour stage in mammary and endometrial carcinoma. Kaplan-Meier analysis 
examining the association of tumour expression of hGH and/or hPRL with 
relapse free survival (RFS) and overall survival (OS) of patients revealed an 
unfavourable RFS and OS for mammary carcinoma patients with tumour hGH 
and/or hPRL expression (Figure 1-18) [132]. Similar trend is also observed in 
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mammary carcinoma [132]. Given that autocrine expression of hGH has been 
shown to possess oncogenic potential in mediating mammary carcinoma 
progression in vitro and correlate with clinicopathological features observed in 
ER+ mammary carcinoma, it may also contribute to oncogenic manifestation 
in HER2+ breast cancer. Therefore, determining the role of hGH in HER2+ 
breast cancer biology will advance the understanding of the oncogenic 
properties of this molecule. Moreover, it helps to assess the viability of hGH 
as a potential target of therapies for intervention against HER2+ breast cancer, 














The aim of the present study is to:   
• Investigate the role of autocrine hGH in HER2+ breast carcinoma cells 
by forced expression of the hGH (GH1) gene in HER2+ breast 
carcinoma cell lines BT474 and SkBR3;   
• Determine if forced expression of hGH abrogated HER2+ breast 
carcinoma cells to HER2-targeted therapies such as Herceptin or 
Lapatinib inhibition; 
• Investigate synergistic inhibitory effects of GHR-antagonists and 
HER2-targeted therapy in hGH-overexpressing BT474 and SkBR3 
mammary carcinoma cells; 
• Examine the role of hGH in Herceptin-resistance HER2+ breast 










3 MATERIALS AND METHODS 
3.1 Breast Carcinoma Cell Lines 
The human mammary carcinoma cell lines BT474 and SkBR3 were obtained 
from the American Type Culture Collection (ATCC). The BT474 cell line was 
cultured in RPMI 1640 media (Nacalai Tesque, Japan) supplemented with 2 
mM L-glutamine, 10% heat-inactivated fetal bovine serum (FBS) (Biowest, 
France), 100 U/ml penicillin and 100 µg/ml streptomycin (Biowest, France). 
The SkBR3 cell line was cultured in McCoy’s 5A media supplemented with 2 
mM L-glutamine, 10% heat-inactivated FBS, 100 U/ml penicillin and 100 
µg/ml streptomycin.  
Cells were cultured in 75 cm2 filtered flasks and incubated in 37oC humidified 
5% CO2 incubator. Media was changed every 2-3 days. Once cells reached 60-
70% confluent, cells will be trypsinized and seeded for functional assay. 
3.2 Cell Transfection 
For generation of hGH expression cell lines, BT474 and SkBR3 cells were 
stably transfected with an empty pcDNA3.1 vector (pcDNA-vec) as a control 
or the same pcDNA vector containing the entire hGH gene (pcDNA-hGH). 
These BT474 and SkBR3 transfected cell lines were designated BT474-Vec 
and BT474-hGH, and SkBR3-Vec and SkBR3-hGH respectively. 
For stable transfection, cells were cultured in 25 cm2 filtered flasks until 70% 
confluence and transfected using FuGENE 6 Transfection Reagent (Promega) 
according to the manufacturer’s protocol. First, serum free media was mixed 
with FuGENE 6 transfection reagent at 3:1 ratio for both BT474 and SkBR3 
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cells in 1.5 ml tubes and incubated at room temperature for 15 minutes. 
Subsequently, 1.0 µg of plasmid DNA was added into the tube and incubated 
at room temperature for 30 minutes. During this incubation period, culture 
media was removed from 25 cm2 flasks and cells were washed with phosphate 
buffered saline (PBS). Thereafter, 4 ml of serum-free media was added to the 
flask. The FuGENE/DNA complex solution was then added directly drop-wise 
to the cells. Following 6 hours of incubation at 37oC, 2 ml of complete media 
was added to each flask.  
Pooled stable transfectants were selected with the respective complete media 
containing 800 µg/ml (BT474) and 1,000 µg/ml (SkBR3) G418 (Sigma-
Aldrich) for 3-4 weeks. During the period of selection, the media was changed 
every 2 days. Subsequently, stable transfectants were expanded and vials of 
each cell lines were frozen and stored.  
3.3 Drug Treatments  
Herceptin was kindly provided by Dr Goh Boon Cher from National 
University Hospital and Cancer Science Institute of Singapore. The working 
concentration of Herceptin used for functional assay was at 50 µg/ml media. 
An equivalent concentration of IgG was added to the control wells.  
For functional assays involved the use of Lapatinb, drug treatment 
concentration (IC50) was determined by performing dose response curve. Cells 
were seeded at 2 x 103 cells per 96-well plates in triplicate. Subsequently, 0, 1, 
10, 100, 1,000 and 10,000 nM concentration of drugs was added to the cells 
and incubated for 48 hours. Cell viability was determined using Alarma Blue 
(Invitrogen) by measuring fluorescence reading. The working concentration of 
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Lapatinib for functional assay using BT474-Vec/hGH and SkBR3-Vec/hGH 
stable cells was determined at 150 nM and 15 nM respectively. An equivalent 
amount of DMSO was added to the control wells. 
3.4 Herceptin-Resistance Cell Lines 
Both BT474 and SkBR3 Herceptin-acquired resistance clones were generated 
by constantly treating the parental cell line with 10 µg/ml and 50 µg/ml 
Herceptin respectively in 25cm2 filtered flasks for a period of 6 months. Fresh 
media containing Herceptin was replaced every 3 days.  
3.5 Total RNA extraction 
Total RNA was isolated from BT474-Vec, BT474-hGH, SkBR3-Vec and 
SkBR3-hGH cell lines using RNase extraction kit (Qiagen). Cells were lyzed 
by adding 1 ml Lysis Buffer/10 cm culture dishes, and an equal volume of 
70% ethanol were added to the cell lysate in 1.5 ml tube. Subsequently, the 
lysate was subjected to the columns provided from the kit and centrifuged at 
13,000 x g for 15 minutes at 4oC. The columns were washed twice using the 
Wash Buffers provided and eluted in RNase-free water provided in the kit. 
The concentration of RNA was determined by Nanodrop. Purity of RNA was 
also determined using the ratios A260/A280nm and A260/A230nm.  
To avoid genomic DNA contamination in subsequent gene expression 
analysis, the extracted RNA was treated with Dnase I (Invitrogen) according 




3.6 Reverse transcription (RT) and Polymerase Chain Reaction (PCR) 
Concentration of extracted total RNA was determined by Nanadrop prior to 
RT reaction. Total RNA was converted to cDNA using Superscript VILO 
cDNA kit (Invitrogen) according to manufacturer’s instruction. All reagents 
were placed and procedure prepared on ice. The cDNA was either stored -
20oC or used immediately for PCR.  
Polymerase chain reaction (PCR) was performed using the Platinum High 
Fidelity PCR kit (Invitrogen) based on the protocol provided by manufacturer. 
The hGH, hPRL, hGHR, hPRLR and β-actin primers with its respective 
appropriate annealing temperature and cycle number were stated below: 




































































For parental or wild-type cells, the PCR cycle for detection of hGH gene is 40. 
For hGH-stably transfected BT474 and SkBR3 cells, 35 cycles was used for 
detecting hGH gene expression. 
3.7 Protein Extraction  
Cells were seeded on 10 cm tissue culture dishes at 70% confluence, and 
changed into serum free media the following days for 24 hours. Cells were 
washed twice with ice cold PBS and harvested in lysis RIPA buffer (2 M 
NaCl, 10% Na-deoxycholate, 10% SDS, Triton X-100, 1 M Tris-HCl and 
Water) containing cocktail protease (1st Base Pte Ltd) and phosphatase 
inhibitors (Calbiochem) by mechanical scraping. Lysates were incubated for 
30 minutes on ice with vortexing every 5 minutes.  Following incubation, 
lysates were centrifuged at 13,000 rpm for 10 minutes at 4oC. The cell pellet 
which consists of cell debris was discarded. The supernatant was transferred 




3.8 Protein Quantification 
Protein quantification was measured in triplicate using DC Protein Assay 
(Bio-Rad Laboratories Pte Ltd). A set of standard solutions (0, 1, 2, 4, 6, 8 and 
10 µg/ml) were prepared using Bradford reagent (Bio-Rad Laboratories Pte 
Ltd). First, 22 μl of DC Reagent A was added into each well of 96-well plate, 
followed by 1 µl of either protein standards or samples. Subsequently, 176 µl 
of DC Reagent B was added to each well. The plate was incubated in dark at 
room temperature for 15 minutes for colourmetric reactions to take place. 
Protein concentration was determined by reading absorbance at 750 nm using 
TECAN i-control plate reader. Based on the absorbance of standards, a 
standard curve was plotted, and concentration of protein sample was 
determined using equation generated from the standard curve.  
3.9 Conditioned Media  
Cells were seeded at 3 x 104 in 10cm2 tissue culture dish until 60-70% 
confluence, and subsequently culture media was changed to serum free for 24 
hours. The cell culture supernatant was then collected and subjected to 
ultracentrifugation at 7,500 x g for 40 minutes using 10 kDa MWCO 
Ultrafilters concentrators (Millipore). The flow-through was discarded and the 
section retained in the concentrator was collected for subsequent western blot 
or ELISA analysis as this fraction was where the secreted hGH (22 kDa) be 
found. For western blot analysis, equal amount of laemmli loading buffer 
(Bio-Rad Laboratories Pte Ltd) containing β-mercaptoethanol (Sigma-Aldrich) 
was added to the supernatant prior to boiling at 99oC. For subsequent ELISA 
analysis, the collected conditioned media was stored at -80oC before use. 
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3.10 Protein Electrophoresis and Western Blot 
Protein extracted from whole cell lysate and conditioned media were resolved 
by 10% Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-
PAGE) at 80 V for stacking gel (1 M Tris-HCl pH 6.8) and subsequently 120V 
for resolving gel (1.5 M Tris-HCl pH 8.8) in 1X Tris/Glycine/SDS buffer. For 
detection of HER2 or pHER2, whole cell protein extract was resolved by 6% 
SDS-PAGE gel under the same condition. For western blot, the resolved gel 
was transferred onto polyvinylidene floride (PVDF) membrane (Bio-Rad 
Laboratories Pte Ltd) using 1X Glycine/Methanol transfer buffer at 100 V at 1 
to 1.5 hours. The PVDF membrane was activated in methanol and washed in 
water prior to use for western blot. Blocking was done using 5% BSA/PBST 
(Bovine serum albumin in Phosphate-buffered saline with 1% Tween 20) for 
2-4 hours at room temperature. Thereafter, the membrane was incubated 
overnight at 4oC with primary antibodies: rabbit anti-hGH (1:2,000) (Dr 
Parlow, National Hormone and Peptide Program, Torrance, CA), rabbit anti-
HER2 (1:500) (Abcam), rabbit anti-Phospho-HER2 (Y1248) (1:1,000) 
(Abcam), and mouse anti-β-actin (1:5000) (Santa Cruz) as loading control. 
Subsequently, the membrane was washed thrice with PBST for 10 minutes. 
Subsequently, the membrane was incubated with the appropriate secondary 
anti-rabbit or anti-mouse antibody (Sigma-Aldrich) at 1:10,000 for 1 hour, and 
again washed thrice with PBST. Lastly, protein bands were detected using 
horseradish peroxidase western blot detection system (Supersignal West Pico 
and Femto Chemiluminescence substrate, Pierce, Life Technology) and film 
(Konica Minolta Fujifilm) was developed using Kodak Medical X-Ray 
Processor (Carestream Health).  
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3.11 hGH Enzyme-linked immunosorbent assay (ELISA)  
The hGH ELISA kit (Roche) was used to quantitatively measure the 
expression levels of secreted hGH released into cell culture supernatant of 
eukaryotic cells transfected with plasmid containing hGH gene. The procedure 
for ELISA was carried out according to the manufacturer’s instructions. For 
each sample, 100 μl was added into each anti-hGH-precoated well on the 
ELISA microtitre plate in duplicate. The kit has provided recombinant hGH 
protein (5 ng) as positive control where a standard curve was plotted at 
concentration 0, 12.5, 25, 50, 100, 200 and 400 pg/ml against absorbance 
(A409nm – A490nm). The amount of secreted hGH present in each sample was 
determined from the standard curve generated. Results were expressed as 
concentration of hGH in pg/ml of the media. Every time an ELISA was 
performed, a new standard curve was generated. 
3.12 Total Cell Number  
Cells (BT474-Vec, BT474-hGH, SkBR3-Vec and SkBR3-hGH) were seeded 
in 6-well plates at a density of 1 x 104 cells per well in either 0.5% FBS or 
10% FBS medium. For drug treatment, cells were seeded in 24-well plates at a 
density of 3 x 104 cells per well. Total cell number was counted every 2 days 
for a period of 10 days. Treatment media was changed every third day.  
For cell counting, cells were trypsinized using 1X Trypsin/EDTA (Biowest) 
and subsequently neutralized by adding 1 ml complete media. After that, 10 µl 
of the cell suspension were mixed with 10 µl of trypan blue (Biowest), and 10 
µl of the mixture was loaded on each side of the haemocytometer. Only viable 
cells were counted. Number of cells contained in 4 quadrants of 16 squares 
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was counted twice. The counted squares were then added together and 
averaged. Finally, the total number of cells was determined by the amount of 
cells/ml using the following formula: 
(Number of Cells Counted in all quadrant/4) X 104 X dilution factor = cells/ml 
Cells/ml X final volume of suspension = total no. of cells 
3.13 Soft Agar Colony Formation (SACF) 
Cells were cultured to 60-70% confluence in 75 cm2 flask in complete media. 
For soft agar colony formation assay, cells were seeded in 96-well microtitre 
plates at a density of 1 x 103 cells per well.  
Each well of the 96-well plate was first covered with a base agar layer that is 
made up of 0.5% agarose in serum free RPMI media (BT474-vec and BT474-
hGH) or serum free McCoy’s 5A (SkBR3-vec and SkBR3-hGH) media. This 
base agar layer was allowed to set at room temperature for 30 minutes. 
Subsequently, 0.7% agarose (Bio-Rad Laboratories Pte Ltd) was prepared in 
serum free media and incubated in water bath at 42oC to maintain cellular 
viability and avoid polymerisation of the agar.  
Cells were trypsinized and resuspended in complete media to obtain single cell 
suspension. Equal volume of 0.7% agar was added to equal volume of cell 
suspension to make a final cell suspension in 5% media with 0.35% agarose. 
This mixture was added carefully to each well on the top of the base agar to 
prevent bubbles formation. The plate was left to set at room temperature for 30 
minutes and 100 µl of treatment media was then added to each well. Treatment 
media will diffuse into the semi-solid layer where cells were seeded in 
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suspension. Experiment was performed in triplicate over a period of 12-14 
days. Media was changed every 6-7 days. At day 14, the media was drained 
and alamar blue was added to determine viability of colonies formed by 
measuring fluorescence. Alamar blue was incubated for 3-4 hours. 
Representative pictures of colonies formed were taken using microscope at 
10X magnification. 
3.14 Three-Dimensional (3D) Culture of Cells in Matrigel 
For this assay, cells were plated in 96-well plates at 1 x 103 cells per well in 
4% growth factor reduced MatrigelTM (BD Biosciences) and 5% serum media 
and allowed to form colonies.  
The plate was first coated with 40 µl of 100% Matrigel and allowed to set at 
room temperature for 30 minutes. Subsequently, cells were trypsinized and 
resuspended in 1:1 ratio of serum-free media to complete media to make a 
final cell suspension in 5% media with 4% matrigel. Cells were allowed to 
grow and form colony for a period of 14 days. Treatment media was changed 
every 6-7 days. Cell viability was determined by measuring fluorescence using 
Alamar blue. Representative pictures of colonies formed were taken using 
microscope at 10X magnification.  
3.15 Apoptosis 
Cells were seeded in 96-well black plates at a density of 2 x 104 cells per well 
in either serum-free or 10% FBS or treatment media. After 24 hours of 
incubation, equal volume of ApoCaspase 3/7 reagent (Promega) was added 
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and incubated for 30 minutes. Subsequently, apoptosis was determined by 
measuring caspase 3/7 luminescence activity using TECAN reader.  
3.16 Statistics Analysis 
Graphical presentations were generated using GraphPad Prism 5. The 
statistical analysis was done using GraphPad Prism 5 in conjunction with 
Microsoft Excel. All experiments were performed at least three times and a 
single representative figure is shown. Data is first analysed using F test to 
determine equal variance between two comparing samples. If the p value for F 
test is <0.05, statistical significance will be computed using Student’s unpaired 
two-tailed equal variance t test. However, if p value for F test is >0.05, 
statistical significance between two comparing samples will then be computed 
using Student’s unpaired two-tailed unequal variance t test. Numerical data 










4.1 Endogenous hGH expression in HER2+ mammary carcinoma cells 
Four HER2-overexpressing mammary carcinoma cell lines, BT474, MDA-
MB-361, SkBR3 and MDA-MB-453, were selected in this study for screening 
of endogenous hGH mRNA and protein expression. Besides being classified 
as HER2-amplified cells, BT474 is ER+/PR+, MDA-MB-361 is ER+/PR-, 
while SkBR3 and MDA-MB-453 are both ER-/PR-. As indicated in Figure 4-
1A, it showed that these 4 HER2+ mammary carcinoma cell lines expressed 
differential endogenous level of hGH transcripts. All cell lines expressed the 
hGHR and hPRLR, which are receptors for hGH ligand [88, 90]. Similarly, all 
cell lines expressed differential levels of endogenous hGH proteins from the 
whole cell lysate (Figure 4-1B).  
From figure 4-1, the mRNA expression of hGH from BT474, MDA-MB-361, 
SkBR3 and MDA-MB-453 differed from its respective protein expression 
levels which were obtained from whole cell lysate. One explanation would be 
hGH being a secretory protein and hence the endogenous hGH produced by 
the different cell lines may be in the secreted form. As a result, protein 
extracted from whole cell lysate may not correlate with its expression at the 
gene level. Therefore, an ELISA was carried out to quantify the amount of 
secreted hGH from the 4 different HER-amplified cell lines, which may better 
correlates with its respective mRNA expression levels. 
 
 



































































































































































































































































transfected in BT474 and SkBR3 cells using FuGene 6 transfection reagent. 
The empty pcDNA vector was also transfected into both cell lines as control. 
The resultant transfectants BT474-Vec, BT474-hGH and SkBR3-Vec, SkBR3-
hGH stable cell lines were verified by RT-PCR, western blot and ELISA.  
As shown in Figure 4-3, the BT474-hGH and SkBR3-hGH cells significantly 
expressed high levels of hGH mRNA and protein as compared to their 
respective BT474-Vec and SkBR3-Vec control cells, indicating effective 
forced expression of hGH in both cell lines. Concomitantly, western blot 
analysis on the cell culture supernatants revealed significant elevated levels of 
secreted hGH protein in BT474-hGH and SkBR3-hGH cells compared to 
control cells. In addition to the predominant 22 kDa hGH, western blot 
detected the 20 kDa hGH isoform protein in both BT474-hGH and SkBR3-
hGH cells. This smaller molecular weight hGH isoform protein was derived 








































 of hGH w
due to the 
s, hGH EL






 in BT474 a
in stably tran
 demonstrate

































































































































































































































(C and D) T













lls over a pe
GH cells in
otal cell num













































ure 4-5B).  
R3-Vec and 








































serum condition and promoted significant cell survival and proliferation when 
compared to its respective SkBR3-Vec cells. 
4.4 Forced expression of hGH decreased BT474 and SkBR3 cells from 
serum deprivation-induced apoptosis 
Next, I investigated the effect of forced expression of hGH in BT474 and 
SkBR3 cells on apoptosis by measuring caspase 3/7 activity. Caspase 3 and 
caspase 7 are two of the early cell death effectors in apoptosis pathway. 
Activation of these effector caspases mediate cleavage of regulatory proteins 
and housekeeping proteins involved in apoptosis, resulting in DNA 
fragmentation and eventually removal of cells [134]. Therefore, measuring of 
caspase 3/7 activity will be useful as indicator of apoptotic events in cells. As 
shown in Figure 4-6, the caspase 3/7 activity of BT474-hGH was observed to 
be significantly lower as compared to BT474-Vec. A similar trend was 
observed for SkBR3-Vec/hGH cells where SkBR3-hGH cells exhibited lower 
induction of apoptosis in comparison with SkBR3-Vec cells. Such 
observations demonstrated that autocrine expression of hGH protected HER2+ 
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In addition, the 3D growth of BT474-Vec/hGH cells was assessed by culturing 
cells in growth factor-reduced MatrigelTM in reduced serum (5% FBS) 
conditions. Forced expression of hGH in BT474 cells markedly increased 
colonies formation in 3D MatrigelTM over a period of 14 days, indicating 
enhanced cell growth (Figure 4-7C). The BT474-hGH cells were observed to 
form large colonies as compared to its respective BT474-Vec control cells 
(Figure 4-7C image). Therefore, autocrine hGH possessed oncogenic 
transforming potential that is capable of increasing survival and enhancing 
anchorage-independent potential and 3D growth of BT474 cells. 
4.6 Forced expression of hGH in SkBR3 cells enhanced growth in 3D 
MatrigelTM, but has no effect on anchorage-independent growth 
The SkBR3-Vec/hGH cells were cultured in soft agar as well. However, there 
is no significantly difference between SkBR3-Vec and SkBR3-hGH cells in 
soft agar, therefore autocrine expression of hGH in SkBR3 has no effect on 
anchorage-independent growth. The SkBR3-Vec/hGH cells were cultured in 
3D growth factor-reduced MatrigelTM to assess oncogenic growth ability that 
more closely mimics the in vivo situation. 
In the 3D MatrigelTM assay, SkBR3-hGH cells exhibited significant formation 
of viable and larger colonies when compared to SkBR3-Vec control cells over 
a period of 14 days (Figure 4-8). The SkBR3-hGH cells were observed to form 
larger colonies, while SkBR3-Vec cells either formed few colonies or did not 
form colonies (remained single cells).  Hence, autocrine expression of hGH 
increased growth potential of SkBR3 cells by enhancing colony formation in 
3D.  
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Here, the cell viability assay demonstrated that autocrine expression of hGH in 
BT474 and SkBR3 reduced cell sensitivity to Herceptin- or Lapatinib-induced 
growth inhibition and enhanced cell viability after drug treatment.  
4.9 Forced expression of hGH protected BT474 and SkBR3 cells from 
Herceptin and Lapatinib-induced apoptosis 
Next, apoptosis of BT474-Vec/hGH and SkBR3-Vec/hGH cells was assessed 
by measuring caspase 3/7 activity in the presence of Herceptin or Lapatinib. It 
was shown that autocrine expression of hGH protected BT474 and SkBR3 
cells against apoptosis induced by Herceptin or Lapatinib (Figure 4-12). 
As shown in Figure 4-12A and 4-12B, the BSA- and DMSO-treated BT474-
hGH exhibited significantly reduced caspase 3/7 activity when compared to its 
control BSA- and DMSO-treated BT474-Vec cell lines by 1.5 folds and 2.4 
folds respectively. Similar trend was observed in SkBR3 cells where forced 
expression of hGH resulted in marked decreased in caspase 3/7 activity as 
compared to its respective BSA- and DMSO-treated SkBR3-Vec cells (Figure 
4-12C and 4-12D).  
Following treatment with Herceptin, BT474-Vec cells exhibited significantly 
higher caspase 3/7 activity than BT474-hGH cells by 1.7 folds (Figure 4-12A). 
When expressed as fold difference of BSA-treated BT474-Vec control cells, 
forced expression of hGH reduced the effect of Herceptin-induced inhibition 
on BT474 caspase 3/7 activity by 0.8 fold than Herceptin-treated BT474-Vec 
cells (1.5 folds). Such observation indicated that the presence of autocrine 
hGH protects BT474 cells from apoptosis.   
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In Figure 4-12B, a more striking effect was observed with Lapatinib-treated 
BT474-Vec cells where it exhibited a significant increase in apoptosis by 2.4 
folds in comparison to its respective DMSO-treated BT474-Vec control cells 
(p < 0.05). When expressed as fold difference to DMSO-treated BT474-Vec 
control cells, autocrine hGH reduced the effect of apoptotic inhibition by 
Lapatinib on BT474 (1.9 folds) as compared to Lapatinib-treated BT474-Vec 
cells (2.4 folds). Such observations demonstrated that forced expression of 
hGH also protected BT474 cells from Lapatinib-induced apoptosis.  
Upon Herceptin treatment, SkBR3-Vec cells exhibited enhanced significant 
apoptosis as measured through caspase 3/7 activity by 1.4 folds (Figure 4-
12C) when compared to BSA-treated SkBR3-Vec cells. When comparing to 
the BSA-treated SkBR3-Vec control cells, I observed that Herceptin-treated 
SkBR3-hGH cells (1 fold) reduced caspase 3/7 activity than Herceptin-treated 
SkBR3-Vec cells (1.4 fold). Similar trend was observed in the Lapatinib 
treatment group on SkBR3 stable cells, where caspase 3/7 activity in 
Lapatinib-treated SkBR3-hGH cells (1.3 fold) was reduced as compared to 
Lapatinib-treated SkBR3-Vec cells (1.8 fold) relative to DMSO-treated 
SkBR3-Vec cells (Figure 4-12D). Herein, I observed that SkBR3 cells were 
protected from apoptosis in the presence of autocrine expression of hGH. 
Based on cell viability and apoptosis functional assay done with the use of 
therapeutic drugs, autocrine expression of hGH enhanced survival of BT474 
and SkBR3 HER2+ mammary carcinoma cells by increasing cell growth and 
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4.11 Autocrine hGH enhanced BT474 and SkBR3 cell growth capacity in 
3D-matrigel after Herceptin or Lapatinib treatment 
In 3D growth assays, the BT474-hGH cells exhibited significantly increased 
cell viability as compared to its respective BT474-Vec cells (Figure 4-14A and 
B). The presence of Herceptin significantly inhibited viability of BT474-Vec 
cells. Importantly, Herceptin-treated BT474-hGH cells still exhibited 
enhanced cell viability in 3D matrigel compared to Herceptin-treated BT474-
Vec cells. A similar trend was observed when BT474-Vec and BT474-hGH 
cells were treated with Lapatinib (Figure 4-14C and D). Taken together, soft 
agar colony formation and 3D Matrigel growth assays demonstrated that 
autocrine hGH expression in BT474 cells significantly enhanced anchorage-
independent growth and increased viability capacity in 3D after exposure to 
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The HER2+ subtype breast cancer is found in 20-30% of invasive breast 
cancer and associated with unfavourable prognostic outcome. Advanced and 
metastatic HER2+ breast cancer patients often exhibit tumour relapse and poor 
survival outcome [55, 138]. Preclinical studies have shown that in HER2+ 
breast cancer, the HER pathway which governs growth, survival and 
proliferation, is overly active [139]. These continuous signals can lead to 
uncontrolled cell growth and potentially contribute to cancer progression. The 
development of a recombinant therapeutic drug known as Herceptin that 
targets HER2 to block its activity has been approved for treatment of patients 
diagnosed with HER2+ breast cancer [52, 57]. However, de novo and acquired 
resistance to the treatment is still a major challenge faced in clinics when 
treating this particular subtype of breast cancer patients. For instance, the 
response rates of Herceptin monotherapy in metastatic breast cancer study is 
found to be 11-26%, indicating de novo resistance [62]. Disease recurrent or 
relapse is reported in HER2+ breast cancer patients after one year treatment 
with Herceptin [49, 52]. Treatment using another drug, Lapatinib, for HER2+ 
breast cancer patients has also been proven to be successful and effective in 
the blockage of HER2 and EGFR signalling activities, but eventually becomes 
limited due to emergence of acquired drug resistance as well. Such 
observation implies that HER2 alone is inadequate as predictive marker to 
delineate the treatment for HER2+ breast cancer patients. Besides that, it 
indicates the presence of alternative mechanisms or compensatory pathways in 
which cancer cells can utilize as survival strategies where blocking of HER2 
alone as one molecular target is thus insufficient in therapy. The existence of 
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disease relapse indicates the need to examine the mechanisms underlying 
tumour resistance to the treatment. Furthermore, there is the necessity to assess 
additional biomarkers or alterative combinations therapies that have inhibitory 
functions different from that of HER2-targeted agents for improved treatment 
and overall survival for patients with metastatic HER2+ breast cancer.  
The association of GH expression has been identified in an increasing number 
of cancers including breast, endometrial, lung, colon and liver [124, 125, 140-
143]. Additionally, autocrine expression of hGH is reportedly correlated with 
clinicopathological features in ER+ mammary carcinoma malignancies 
implying that tumour expression of hGH is a potential predictive marker 
during breast cancer prognosis [132]. Recently, a clinical study performed on a 
cohort of breast and endometrial carcinomas patients have shown 
overexpression of tumour hGH mRNA and protein to be positively correlated 
with HER2 positivity (P = 0.004 and P = 0.001 respectively) and lymph node 
metastasis (P = 0.002). These patients whose tumour expressed high level of 
hGH have a significant poorer overall survival and relapse free survival in 
comparison to those whose tumour are hGH-negative. Therefore, it is worth to 
investigate the possible functional interaction between hGH and HER2 in 
order to better understand the oncogenic progression of HER2+ tumours and 
the mechanisms of resistance in treating HER2+ breast cancer patients. 
Furthermore, it may allow the intervention of targeted therapy for breast 
cancer patients whose tumour is HER2+ and hGH+ by blocking GH activity as 
adjuvant therapy in combination with current HER2-targeting agents.  
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Herein, this study explored the role of autocrine hGH in HER2+ breast 
carcinoma cells, and the potential of targeting both hGH and HER2 by 
combining GHR antagonists and Herceptin or Lapatinib as a possible 
alternative therapy. It was demonstrated that in the presence of autocrine 
expression of hGH, the HER2-amplified BT474 and SkBR3 breast carcinoma 
cells have significantly increased viability and growth potentials in anchorage-
independent manner. In the present study, it showed that forced expression of 
hGH in BT474 and SkBR3 cells increased total cell number in vitro. 
Concomitantly, a decreased in caspase 3/7 activity was observed, thereby 
indicating autocrine expression of hGH protected BT474 and SkBR3 cells 
from apoptosis induced by serum deprivation. Additionally, BT474-hGH cells 
were observed to exhibit increased viability in soft agar colony formation and 
3D matrigel assays compared to its respective control cells, which implied that 
cell growth was significantly enhanced in the presence of autocrine hGH. 
Similarly, SkBR3-hGH cells exhibited significant enhanced viability in 3D 
matrigel as compared to its control cells. These observations implied that 
forced expression of hGH promotes and enhances viability and growth 
potential of HER2+ breast carcinoma cells. One mechanism by which 
autocrine hGH increases oncogenic potential and promotes cell survival of 
HER2+ breast cancer cells was through stimulating tyrosine phosphorylation 
(Y1248) of HER2, which serve as the major autophosphorylation sites of 
HER2 [135]. It is reported that HER2 activation of the ERK pathways is 
primarily dependent on Y1248 phosphotyrosine residues on the intracellular 
domain of HER2 [144]. The phosphorylation of Y1248 residue resulted in the 
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recruitment and association of SHC with HER2. Mutation or deletion of this 
phosphotyrosine residue significantly diminished ERK activation.  
HER2+ breast cancer is quite heterogeneous and it can be further sub-divided 
into hormone receptor-positive (ER+/PR+/HER2+) or hormone receptor-
negative (ER-/PR-/HER2+). The BT474 cell line belongs to the hormone 
receptor-positive, while SkBR3 cell line is hormone receptor-negative. The 
results observed in this study is thus independent of hormonal receptor status 
(ER and PR) as forced expression of hGH enhances oncogenic capacity in 
both BT474 and SkBR3 through increasing total cell number, enhancing 
anchorage-independent growth and cell growth in 3D, stimulating 
phosphorylation of HER2 (Y1248) and decreasing apoptosis. Besides that, 
autocrine hGH was found to reduce BT474 and SkBR3 HER2+ carcinoma 
cells sensitivity to Herceptin or Lapatinib therapeutic drug treatment with the 
exception that no significant difference in anchorage-independent growth of 
BT474 in the presence of Lapatinib. 
It has been reported that expression of autocrine hGH is associated with 
therapeutic resistance including tamoxifen [123], doxorubicin [120], MMC 
[124] and even ionising radiation [125]. Here, it was further demonstrated that 
both Herceptin- or Lapatinib-treated hGH-overexpressing BT474 and SkBR3 
cells exhibited enhanced total cell number, increased colony formation and 
survival in 3D and reduced apoptosis. Therefore, autocrine expression of hGH 
provided a selective growth advantage for BT474 and SkBR3 HER2+ 
mammary carcinoma cells in the presence of therapeutic protocol containing 
Herceptin and exerted less oncogenic effect in the presence of Lapatinib. 
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Treatment with Lapatinib was observed to be more effective than Herceptin in 
achieving growth inhibition as viability of Lapatinib-treated BT474-Vec/hGH 
and SkBR3-Vec/hGH cells was significantly lower than that of Herceptin-
treated BT474-Vec/hGH and SkBR3-Vec/hGH cells. This also explains why 
Lapatinib is often used as the preferred agent in combination with other 
chemotherapeutics for treating HER2+ breast cancer patients when Herceptin 
fails. 
Unpublished work performed by other graduate students in my laboratory 
working on breast cancer EMT have observed an increase in invasion, 
migration potential, and enhancement in closing of artificially-inflicted 
wounds in the presence of autocrine hGH in BT474 and SkBR3 HER2+ breast 
carcinoma cells. Besides that, autocrine expression of hGH greatly enhanced 
the mammo-spheroid formation, the Aldehyde Dehydrogenase-positive 
(ALDH+) and stem cell side population in SkBR3 and MDA-MB-453 
(HER2+/ER-) breast carcinoma cells. Additionally, immunodeficient mice 
injected with hGH-overexpressing MDA-MB-453 cells formed tumours in the 
mammary fat pad as compared to those injected with control cells. These 
studies clearly reiterated the oncogenic role of autocrine hGH to increase 
proliferation, survival, anchorage-independent growth, promote invasion and 
migration as well as enhance tumour-initiating or cancer stem cells population 
in HER2+ mammary carcinoma cells in vitro and formation of tumours in 
vivo.  
Breast cancer is a heterogeneous disease and oncogenesis is driven by multiple 
signalling pathways. During the process of oncogenesis, cells acquire one, two 
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or more typical traits of cancer hallmarks as it accumulates mutation. 
Therefore, a multi-targeted therapeutic approach will greatly offer advantages 
for breast cancer treatment, in particularly to overcome drug resistance that 
has become more prevalent. As presented in this study that autocrine hGH is 
able to increase oncogenic transformation potential of HER2+ breast cancer 
cells and decrease the cells sensitivity to Herceptin or Lapatinib, blocking or 
reducing of hGH in circulation may hence decrease proliferative and 
oncogenic capacities, thereby providing additive effects to Herceptin or 
Lapatinib inhibition. If synergistic inhibition by combining GHR antagonists 
and HER2-targeted agents is efficacious, this could be an option of targeted 
therapy available for the subgroup of breast cancer patients with 
HER2+/hGH+ tumours. I therefore went on to investigate the effectiveness of 
using GHR antagonists such as G120R [145] or B2036 [107, 108, 146] to 
block endogenous hGH in BT474 and SkBR3 cells and hypothesize that a 
combination of both GHR antagonists and HER2-targeted agent can 
significantly decrease oncogenic transforming potential of HER2-amplified 
breast cancer cells compared with either agent alone.  
Two approaches were attempted to functionally antagonise or inhibit 
endogenous GH, which include the use of G120R and B2036. The G120R 
consists the entire hGH1 gene with a single point mutation that involves the 
substitution of an arginine (R) for glycine (G) at residue position 120 [147]. 
This mutation is introduced within the region where binding site 2 of GH is 
located which blocks receptor dimerization; thus G120R acts as an antagonist 
to GH. It is cloned into the pcDNA3.1 plasmid backbone to generate pcDNA-
G120R and was stably transfected into BT474 and SkBR3 cells to generate 
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BT474-G120R and SkBR3-G120R respectively. Monolayer total cell number 
assay shows that both BT474-G120R and SkBR3-G120R cells exhibited 
significantly lower total cell number in comparison to its respective BT474-
Vec/BT474-hGH and SkBR3-Vec/SkBR3-hGH cells gradually over a period 
of 10 days (results not shown). In contrast, the hGH-overexpressing BT474 
and SkBR3 cells exhibited the highest total cell count, followed by its 
respective BT474-Vec and SkBR3-Vec control cells. Besides that, BT474-
G120R cells have reduced ability to form viable colonies in soft agar, 
indicating significant decrease in anchorage-independent growth capability 
(results not shown). Such observations were consistent with our hypothesis 
where overexpression of hGH will enhance proliferative, survival and cell 
transforming capacities, while antagonism of hGH will abrogate its oncogenic 
transforming potential in HER2-amplified cells. However, the pool of G120R-
transfected cells selected out after the 3rd passage in culture. The second GHR 
antagonist used is the B2036 derived from eight amino acid substitution at 
binding site 1 that enhances its affinity to GHR and a single point mutation of 
glycine to lysine residue at position 120 (GÆK) at binding site 2 that blocks 
GH dimerization and signalling [146]. 
Dose-response curve was done to determine the IC50 of B2036 to be used on 
BT474 and SkBR3, but the results I generated indicated that both BT474 and 
SkBR3 wild-type cell lines do not respond to this antagonist in the assays I 
utilized (data not shown). Therefore, it is not possible to use B2036 in both 
BT474 and SkBR3 cell line model generated in our lab. It will be ideal to 
observe positive outcome where the presence of B2036 will cause BT474 and 
SkBR3 HER2+ mammary carcinoma cells to exhibit significant reduction in 
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proliferation and survival. Nevertheless, the use of pcDNA-G120R plasmid in 
BT474 and SkBR3 do demonstrate that cell viability and growth potential 
were markedly reduced when GH signalling was blocked.  
Like other in vitro drug assays or clinical settings, it appeared that cell lines or 
patients responsiveness to an agent/inhibitor/drug such as B2036 varied. 
Functional inhibition of GH using B2036 have been performed on MDA-MB-
453 (HER2+/ER-) cell by another student in my laboratory who is working on 
the role of hGH in enhancing cancer stem cells population in ER- mammary 
carcinoma cells. It is demonstrated that upon treatment with B2036, MDA-
MB-453 cells exhibited marked reduction in the ability to form mammo-
spheroids in culture. Such observation demonstrated effective blockage of GH 
action by B2036 and that can greatly reduce viability and growth of MDA-
MB-453 HER2+ mammary carcinoma cell. However, MDA-MB-453 cell is 
not suitable as the in vitro model in my study because it is Herceptin-
resistance cell line, unlike BT474 and SkBR3 which are both Herceptin- and 
Lapatinib-responsive.  
Other than BT474 and SkBR3, ZR-7530 cell is reported to be one of the three 
out of nine HER2-amplified mammary carcinoma cell lines that respond to 
Herceptin [75]. The ZR-7530 cell may thus be an alternative in vitro model 
that is useful to determine synergistic inhibition between GH antagonist and 
HER2-targeted agent in this project. Having said that, ZR-7530 should be 
tested for its endogenous hGH level and subsequently its responsiveness to 
B2036 by performing dose-response experiment.  
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Despite having shown to be beneficial therapeutically based on previous in 
vitro studies on mammary and endometrial carcinomas [22, 117, 122, 124, 
125], there are still limited in vivo studies demonstrating the efficacy of GHR 
antagonists such as B2036 in cancer treatment. Additionally, GHR antagonists 
are yet to be tested in cancer-related clinical trials. There is therefore a need 
for such translational studies to be conducted in order to deduce the feasibility 
or therapeutic potential of introducing GHR antagonists as adjuvant to 
sensitize mammary carcinoma cells that are GH-positive to subsequent cancer-
related therapy for HER2+ subtype breast cancer in this case. Besides G120R 
and B2036, other agents capable of inhibiting GH-mediated signalling should 
also be tested. 
In this project, overexpression of hGH were done in already transformed cells, 
which are BT474 and SkBR3 HER2-amplified breast carcinoma cell lines. 
Previous study conducted by Zhu et al, 2005 have revealed oncogenic 
transformation of normal but immortalized human mammary epithelial cells 
(MCF10A and MCF12-A) transfected with hGH in a JAK2-dependent 
manner, demonstrating that autocrine expression of hGH also drive 
tumorigenesis process in normal cells [122]. Nevertheless, it will be 
interesting to examine in future study on the sensitivity of these hGH-
transfected MCF10A and/or MCF12A normal cells to Herceptin or Lapatinib 
for a better understanding on the role of autocrine hGH in HER2-targeted 
therapies.  
The emergence of resistance to HER2-targeted therapy has suggested 
additional escape pathways involved in contributing to resistant growth that 
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will need to be targeted to fully circumvent such clinical obstacle observed in 
patients with HER2+-refractory breast cancer. It is challenging to elucidate the 
molecular mechanisms of Herceptin-resistance in HER2+ breast cancer due to 
the complexity of signal pathways, which allows cancer cells to utilize 
alternative compensatory route to strive for survival. Nevertheless, multiple 
molecular mechanisms contributing to Herceptin-acquired resistance have 
been described, suggesting that a different targeted-therapeutic approach is 
required during treatment of HER2+ breast cancer. This also explains why 
current clinical strategies where all HER2+ patients are treated with a broad 
similar approach still remains suboptimal. This project aimed to investigate the 
functional interaction between hGH in Herceptin-acquired resistance in vitro. 
Despite being shown to enhance viability and growth potential in HER2+ 
breast carcinoma cell lines, it was demonstrated that hGH is not functionally 
involved in Herceptin-acquired resistance as the expression level of hGH in 
BT474 control/resistance cell and SkBR3 control/resistance cell remained the 
same. 
In summary, this study provided an understanding on the role of autocrine 
hGH in enhancing cell viability and growth of HER2+ subtype breast 
carcinoma cells. Forced expression of hGH provided a selective growth 
advantage for HER2-amplified cells by reducing sensitivity to HER2-targeted 
agents such as Herceptin or Lapatinib. In addition, tumour expression of hGH 
may hold significance to being an additional biomarker for treating breast 
cancer patients whose tumour co-expresses HER2 and hGH. Nevertheless, 
more work is still needed to verify therapeutic potential or efficiency of 
combination strategies that functionally inhibits hGH together with 
101 
 
conventional therapies, which together may provide optimal therapeutic 




















In conclusion, HER2+ human breast carcinoma cells BT474 and SkBR3 
exhibits significant proliferation, enhances anchorage-independent growth and 
promotes growth in 3D in the presence of autocrine secretion of hGH. 
Additionally, autocrine expression of hGH is able to stimulate tyrosine 
phosphorylation of HER2 (Y1248), thereby activating downstream signalling 
cascade of HER2 pathway. Furthermore, forced expression of hGH reduces 
sensitivity of BT474 and SkBR3 HER2+ breast carcinoma cells to HER2-
targeted therapies including Herceptin or Lapatinib. Besides BT474 and 
SkBR3, other HER2+ breast carcinoma cell line such as ZR-7530 should be 
consider as in vitro model to examine synergistic inhibition and the 
effectiveness of introducing hGH antagonists in combination with HER2-
targeted therapeutic agents. This study provided an insight on functional role 
of autocrine hGH in HER2+ mammary carcinoma progression and 
oncogenesis. Moreover, together with other experimental evidences performed 
by other students in my lab, it suggests that autocrine expression of hGH in 
HER2-overexpressing breast cancer has prognostic and predictive roles, and 
that hGH can potentially serves as an additional therapeutic marker and target 
for new therapeutic strategies that specifically target HER2+ breast cancer 
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